Review

Nutrition in autism spectrum disorders: A review of evidences for an emerging central role in aetiology, expression, and management

  • Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders whose aetiology remains largely unknown, but for which environmental factors appear to be important. Emerging evidences suggest that nutrition may play a major role in the aetiology of ASD; also, specific maternal nutritional-deficiencies appear to be associated with an increased risk in offsprings. In addition, studies are beginning to reveal the beneficial effects of dietary supplementation or restriction in the management of ASD; while at the same time debunking the myths that surround certain purportedly-therapeutic dietary manipulations. In this narrative review (using information from internet databases such as Google scholar, PubMed, Scopus and authoritative texts), we examine the emerging central role of nutrition in relation to aetiology, symptomatology, management, and indices of outcome in ASD; by highlighting available scientific evidences pertaining to the impacts of different dietary manipulations and nutritional supplementation. We also consider the likely future roles of nutrition in ASD, as science continues to grapple with the understanding of a group of neurodevelopmental disorders that are emerging to be largely “nutritional illnesses”.

    Citation: Olakunle James Onaolapo, Adejoke Yetunde Onaolapo. Nutrition in autism spectrum disorders: A review of evidences for an emerging central role in aetiology, expression, and management[J]. AIMS Medical Science, 2018, 5(2): 122-144. doi: 10.3934/medsci.2018.2.122

    Related Papers:

    [1] Hamdy M. Youssef, Najat A. Alghamdi, Magdy A. Ezzat, Alaa A. El-Bary, Ahmed M. Shawky . A new dynamical modeling SEIR with global analysis applied to the real data of spreading COVID-19 in Saudi Arabia. Mathematical Biosciences and Engineering, 2020, 17(6): 7018-7044. doi: 10.3934/mbe.2020362
    [2] Sarafa A. Iyaniwura, Musa Rabiu, Jummy F. David, Jude D. Kong . Assessing the impact of adherence to Non-pharmaceutical interventions and indirect transmission on the dynamics of COVID-19: a mathematical modelling study. Mathematical Biosciences and Engineering, 2021, 18(6): 8905-8932. doi: 10.3934/mbe.2021439
    [3] Salma M. Al-Tuwairqi, Sara K. Al-Harbi . Modeling the effect of random diagnoses on the spread of COVID-19 in Saudi Arabia. Mathematical Biosciences and Engineering, 2022, 19(10): 9792-9824. doi: 10.3934/mbe.2022456
    [4] Pannathon Kreabkhontho, Watchara Teparos, Thitiya Theparod . Potential for eliminating COVID-19 in Thailand through third-dose vaccination: A modeling approach. Mathematical Biosciences and Engineering, 2024, 21(8): 6807-6828. doi: 10.3934/mbe.2024298
    [5] Weike Zhou, Aili Wang, Fan Xia, Yanni Xiao, Sanyi Tang . Effects of media reporting on mitigating spread of COVID-19 in the early phase of the outbreak. Mathematical Biosciences and Engineering, 2020, 17(3): 2693-2707. doi: 10.3934/mbe.2020147
    [6] Lin Feng, Ziren Chen, Harold A. Lay Jr., Khaled Furati, Abdul Khaliq . Data driven time-varying SEIR-LSTM/GRU algorithms to track the spread of COVID-19. Mathematical Biosciences and Engineering, 2022, 19(9): 8935-8962. doi: 10.3934/mbe.2022415
    [7] Tianfang Hou, Guijie Lan, Sanling Yuan, Tonghua Zhang . Threshold dynamics of a stochastic SIHR epidemic model of COVID-19 with general population-size dependent contact rate. Mathematical Biosciences and Engineering, 2022, 19(4): 4217-4236. doi: 10.3934/mbe.2022195
    [8] Allison Fisher, Hainan Xu, Daihai He, Xueying Wang . Effects of vaccination on mitigating COVID-19 outbreaks: a conceptual modeling approach. Mathematical Biosciences and Engineering, 2023, 20(3): 4816-4837. doi: 10.3934/mbe.2023223
    [9] Fang Wang, Lianying Cao, Xiaoji Song . Mathematical modeling of mutated COVID-19 transmission with quarantine, isolation and vaccination. Mathematical Biosciences and Engineering, 2022, 19(8): 8035-8056. doi: 10.3934/mbe.2022376
    [10] Yue Deng, Siming Xing, Meixia Zhu, Jinzhi Lei . Impact of insufficient detection in COVID-19 outbreaks. Mathematical Biosciences and Engineering, 2021, 18(6): 9727-9742. doi: 10.3934/mbe.2021476
  • Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders whose aetiology remains largely unknown, but for which environmental factors appear to be important. Emerging evidences suggest that nutrition may play a major role in the aetiology of ASD; also, specific maternal nutritional-deficiencies appear to be associated with an increased risk in offsprings. In addition, studies are beginning to reveal the beneficial effects of dietary supplementation or restriction in the management of ASD; while at the same time debunking the myths that surround certain purportedly-therapeutic dietary manipulations. In this narrative review (using information from internet databases such as Google scholar, PubMed, Scopus and authoritative texts), we examine the emerging central role of nutrition in relation to aetiology, symptomatology, management, and indices of outcome in ASD; by highlighting available scientific evidences pertaining to the impacts of different dietary manipulations and nutritional supplementation. We also consider the likely future roles of nutrition in ASD, as science continues to grapple with the understanding of a group of neurodevelopmental disorders that are emerging to be largely “nutritional illnesses”.


    The Coronavirus disease 2019 (COVID-19) pandemic is now considered as the biggest global threat worldwide. This disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) which belongs to a group of RNA virus causing respiratory track infection that can range mild to lethal [1]. The first outbreak of COVID-19 was noticed in Hubei province, Wuhan, China [2] in December 2019. Then it spread all over the world so rapidly that the World Health Organization (WHO) revealed the COVID-19 to be a public health emergency and identified it as a pandemic on March 11, 2020. Since December 2019, the first COVID-19 infected person was diagnosed, the COVID-19 quickly spread to all Chinese province and, as of 1 April 2020, to 200 countries and regions with the number of reported infected cases and the number of documented death reached 19 million and 717, 792, respectively [3]. Among these countries, the alarming epidemic situations are in the United States (5, 032, 278 total cases, 162, 804 death cases), Brazil (2, 917, 562 total cases, 98, 644 death cases), India (2, 030, 001 total cases, 41, 673 death cases), Russia (871, 894 total cases, 14, 606 death cases), Italy (249, 204 total cases, 35, 187 death cases), UK (308, 134 total cases, 46, 413 death cases), Spain (354, 530 total cases, 28, 500 death cases), Germany (215, 210 total cases, 9, 252 death cases), France (195, 633 total cases, 30, 312 death cases), and Iran (320, 117 total cases, 17, 976 death cases) as of 8th August, 2020. In particular, the number of infection cases in the United States has grown very fast, the number of reported infected cases increases from 15 to 288, 721 spending 82 days only [3].

    The most alarming part of this disease spread is that the symptoms of this disease are not specific and in many cases the infected person may be asymptomatic (who can infect other persons without showing any symptoms of the disease). The majority of the cases initially have symptoms like common cold which includes dry cough, fever, sore throat, loss of sense of smell, headache, shortness of breathe etc. Moreover, the disease growth of this infection further proceed to acute respiratory distress syndrome which can lead to even death. It is also observed in an age-stratified analysis [4] that the large number of severe cases in particular for the age groups above 60 and having other medical issues like diabetics, kidney problems etc. The COVID-19 virus spreads at large extend between people when they come in close contact with each other and the virus is transmitted through expelled droplets which enter a person's body through various contact routes such as the mouth, eyes or nose. Contact with various surface is another means for contracting the virus. In the absence of a definite treatment modality like appropriate/effective medicine or vaccine, physical distancing, wearing masks, washing hands etc. have been accepted globally as the most efficient strategies for reducing the severity and spread of this virus and gaining control over it at some extend [5]. So, the governments of most of the countries had decided to go for complete lockdown from mid or end of March, 2020. This complete lockdown also affected the economy of those countries in a large extent. So, from the mid of the month of May, 2020, all the countries have taken some policies for unlocking gradually.

    Mathematical models of infectious disease dynamics nowadays became a very useful and important tool for the analysis of dynamics of disease progression, to predict the future course of an outbreak and to evaluate strategies to control an epidemic in recent years. The global problem of the outbreak of COVID-19 has attracted the interest of researchers of different areas. Mathematical modeling based on system of differential equations may provide a simple but comprehensive mechanism for the dynamics of COVID-19 transmission. Several modeling studies have already been performed for the COVID-19 outbreak [6,7,8,9,10,11]. In [12], Lin et. al. suggested a conceptual model for the coronavirus disease started at the end of 2019, which effectively catches the time line of the COVID-19 outbreak. A mathematical model for reproducing the stage-based transmissibility of a novel coronavirus is proposed and analyzed by Chen et al. in [13]. Wu et al. developed a susceptible exposed infectious recovered model (SEIR) based on the reported data from December 31st, 2019 till January 28th, 2020, to clarify the transmission dynamics and projected national and global spread of the disease [14]. They also calculated the basic reproduction number as around 2.68 for COVID-19. Tang et al proposed a compartmental deterministic model that would combine the clinical development of the disease, the epidemiological status of the patient and the measures for intervention. Researchers also found that the value of control reproduction number may be as high as 6.47, and that methods of intervention including intensive contact tracing followed by quarantine and isolation would effectively minimize COVID-19 cases [15]. For the basic reproductive number ($ \mathcal{R}_0 $), Read et al. reported a value of 3.1 based on the data fitting of an SEIR model, using an assumption of Poisson-distributed daily time increments [16]. S. Zhao et al. estimated the mean $ \mathcal{R}_0 $ for 2019-nCoV in the early phase of the outbreak ranging from 3.3 to 5.5 (likely to be below 5 but above 3 with rising rate of reported cases) [17], which appeared slightly higher than those of SARS-CoV ($ \mathcal{R}_0 $: 2–5) [18]. A report by Cambridge University has indicated that India's countrywide three-week lockdown would not be adequate to prevent a resurgence of the new coronavirus epidemic that could bounce back in months and cause several thousands of infections [19]. They suggested that two or three lockdowns can extend the slowdown longer with five-day breaks in between or a single 49-day lockdown. Data-driven mathematical modeling plays a key role in disease prevention, planning for future outbreaks and determining the effectiveness of control. Several data-driven modeling experiments have been performed in various regions [15]. In [20], a compartmental mathematical model is developed to understand the outbreak of COVID-19 in Mexico. This data driven analysis would let us compare how different the outbreak will be in the two studied regions. By this approach, authorities can plan a health care program to control the spread even with limited resources. In Rojas et al. [21], the authors estimated the value of $ \mathcal{R}_0 $ which helped them to predict that in the city of Cali the outbreak under current intervention of isolation and quarantine will last for 5–6 months and will need around 3500 beds on a given during the peak of the outbreak. Some other relevant works where the basic reproduction number is estimated for different countries can be found in [22,23,24,26,25,27,28].

    The most common mathematical formulations which represent the individual transition in a community between 'compartments' describe the situation of individual infection with a significant insight. These compartmental models for disease progression segregate a population into groups depending on each individual's infectious state and related population sizes with respect to time. There is a wide range of mathematical models and approaches adopted by different researchers to develop viable mathematical model to understand the propagation of disease spread for COVID-19 with different model assumptions. In our present work we have proposed and analyzed an ordinary differential equation model to study the COVID-19 disease propagation which consists with initially six compartments namely susceptible, exposed, infected, quarantined, hospitalised and recovered. We have divided the exposed compartment into two sub-compartments (denoted by $ E_1 $ and $ E_2 $) depending on their infectiousness and also divided the infected class into two sub-compartments, namely, asymptomatic $ (I_a) $ and symptomatic $ (I_s) $. Interesting and significant contribution of our work is the consideration of time dependent rate of infection over various periods of time. This variation is adopted into the model in order to capture the effect of lockdown, social distancing etc. which plays a crucial role to reduce the disease spread. Next we have discussed the basic properties of our model and calculated the basic and controlled reproduction number. Final size of the epidemic is also described. We have divided susceptible, exposed and infected classes into two sub-classes each based on their classification or behaviour which is directly responsible for the alteration of rate of disease spread. The classification or division into two different groups may be due to the different age groups, different implementation of distancing measures, proper and improper use of face mask and so on. Then we have calculated the reproduction number and final size of the epidemic for the two group model. Next we have copulated the sensitivity index to identify the parameters of greater interest and then fitted those parameter values with the data of total cumulative cases of COVID-19 for different countries (Germany, Italy, Spain, and UK). Then we have shown that with those best fitted parameter values our model simulation is matching well with the 95$ \% $ confidence interval of the daywise cumulative and daily data for reported cases which proved the viability of our model system. This also depict the fact that nature of the disease transmission is different for different countries depending on the protective measures and policies taken by government, different age distribution of the population, lack of consciousness and many others.

    In the following, we consider a dynamic SEIQR type model for the COVID-19 disease progression. Basically the model consists with Susceptible $ (S) $, Exposed $ (E) $, Infected $ (I) $, Quarantined $ (Q) $, hospitalized $ (J) $ and Recovered $ (R) $ class. In the context of COVID-19, the exposed class is divided into two subclasses namely non-infectious $ (E_1) $ and infectious $ (E_2) $ and the infected class is divided into two sub- classes namely asymptomatic $ (I_a) $ and symptomatic $ (I_s) $, where $ N\, = \, S+E_1+E_2+I_a+I_s+Q+J+R $ and $ N $ is not fixed since deceased individuals are not considered in the model explicitly. The model assumptions are given as follows:

    Susceptible population $ S(t) $: This subpopulation will decrease after an infection due to the interaction with an symptomatic infected individual $ (I_s) $, asymptomatic infected individual $ (I_a) $, infectious exposed individual $ (E_2) $, quarantined $ (Q) $ or hospitalised one $ (J) $. The transmission coefficients will be $ \beta I_s/N $, $ \beta p_1 I_a/N $, $ \beta p_2 E_2/N $, $ \beta p_3 Q/N $ and $ \beta p_4 J/N $ respectively. Here $ \beta $ is rate of infection per unit of time by the symptomatic infected, $ p_1 $, $ p_2 $, $ p_3 $ and $ p_4 $ are the reduction factor of infectivity by $ I_a $, $ E_2 $, $ Q $ and $ J $ respectively compared to $ I_s $ and satisfy the restriction $ 0\leq p_j < 1 $, $ j = 1, 2, 3, 4 $. The rate of change of the susceptible population is expressed in the following equation:

    $ \frac{dS}{dt} = -\frac{\beta S}{N}(I_s+p_1I_a+p_2E_2+p_3Q+p_4J). $

    Exposed polulation $ E(t) $: The exposed population (in the incubation period) is divided into two sub classes: (i) exposed population who are at the beginning of the incubation period and cannot spread the disease $ (E_1(t)) $ and (ii) exposed population who are at the end of the incubation period and can spread the disease $ (E_2(t)) $, hence $ E(t)\, = \, E_1(t)+E_2(t) $. The transfer mechanism from the class $ S(t) $ to the class $ E_1(t) $ is guided by the function $ \frac{\beta S}{N}(I_s+p_1I_a+p_2E_2+p_3Q+p_4J) $ and from the class $ E_1(t) $ to the class $ E_2(t) $ is guided by $ \mu E_1 $, where $ \mu $ is the rate at which individuals of $ E_1 $ class become infectious exposed $ (E_2) $. The population of $ E_2 $ will decrease due to the transfer into the infected class with rate $ \delta $. Thus the rate of change of the exposed population is expressed in the following two equations:

    $ dE1dt=βSN(Is+p1Ia+p2E2+p3Q+p4J)μE1dE2dt=μE1δE2.
    $

    Infected polulation $ I(t) $: The infected population is divided into two subclasses (i) asymptomatic (having no symptoms) $ (I_a(t)) $ and (ii) symptomatic (having symptoms) $ (I_s(t)) $, such that $ I(t)\, = \, I_a(t)+I_s(t) $. The transfer mechanism from the class $ E_2(t) $ to the class $ I_a(t) $ is guided by the function $ (1-\sigma)\delta E_2 $ and from the class $ E_2(t) $ to the class $ I_s(t) $ is guided by the function $ \sigma\delta E_2 $ where $ \sigma $ ($ 0 < \sigma < 1 $) is the fraction of $ E_2 $ that becomes symptomatic infected $ (I_s) $. The population $ I_a $ will decrease due to the transfer into the recovered population with a rate $ \eta $ and $ I_s $ will decrease with a rate $ (\rho_1+\zeta_1+\zeta_2+\zeta_3) $, where $ \rho_1 $ is the rate of mortality due to the infection, $ \zeta_1 $, $ \zeta_2 $ and $ \zeta_3 $ are the rate at which $ I_s $ becomes quarantined, recovered and hospitalised respectively. Thus the rate of change of the infected population is expressed in the following two equations:

    $ dIadt=(1σ)δE2ηIa,dIsdt=σδE2(ρ1+ζ1+ζ2+ζ3)Is.
    $

    Quarantined population $ Q(t) $: This subpopulation will increase due to the transfer from the class $ I_s(t) $ with a rate $ \zeta_1 $ and will decrease with a rate $ (\xi_1+\xi_2) $, where $ \xi_1 $ and $ \xi_2 $ are the rates at which $ Q $ becomes hospitalized and recovered respectively. Thus the rate of change of the quarantined population is expressed in the following equation:

    $ \frac{dQ}{dt} = \zeta_1I_s-(\xi_1+\xi_2)Q. $

    Hospitalized population $ J(t) $: This subpopulation will increase due to the transfer from the classes $ I_s(t) $ and $ Q(t) $ with rates $ \zeta_3 $ and $ \xi_1 $ respectively and will decrease with a rate $ (\rho_2+\nu) $, where $ \rho_2 $ is the rate of mortality due to the infection and $ \nu $ is the rate at which the hospitalized individuals are recovered. Thus the rate of change of the hospitalized population is expressed in the following equation:

    $ \frac{dJ}{dt} = \zeta_3I_s+\xi_1Q-(\rho_2+\nu)J. $

    Recovered population $ R(t) $: This subpopulation will increase due to recovery from the disease from the classes $ I_a(t) $, $ I_s(t) $, $ Q(t) $ and $ J(t) $ with rates $ \eta $, $ \zeta_2 $, $ \xi_2 $ and $ \nu $ respectively. Thus the rate of change of the recovered population is expressed in the following equation:

    $ \frac{dR}{dt} = \eta I_a+\zeta_2I_s+\xi_2Q+\nu J. $

    Hence, the system of differential equations that will model the dynamics of coronavirus spread is:

    $ dSdt=βSN(Is+p1Ia+p2E2+p3Q+p4J),
    $
    (2.1a)
    $ dE1dt=βSN(Is+p1Ia+p2E2+p3Q+p4J)μE1,
    $
    (2.1b)
    $ dE2dt=μE1δE2,
    $
    (2.1c)
    $ dIadt=(1σ)δE2ηIa,
    $
    (2.1d)
    $ dIsdt=σδE2(ρ1+ζ1+ζ2+ζ3)Is,
    $
    (2.1e)
    $ dQdt=ζ1Is(ξ1+ξ2)Q,
    $
    (2.1f)
    $ dJdt=ζ3Is+ξ1Q(ρ2+ν)J
    $
    (2.1g)
    $ dRdt=ηIa+ζ2Is+ξ2Q+νJ,
    $
    (2.1h)

    subjected to non-negative initial conditions $ S(0), E_1(0), E_2(0), I_a(0), I_s(0), Q(0), J(0), R(0)\, \geq\, 0 $.

    Interpretation for the parameters involved with the model (2.1) is summarized in Table 1 for a quick reference. A schematic diagram for the transmission of disease and progression of the individuals from one compartment to another is provided in Figure 1.

    Table 1.  Description of parameters involved with the model (2.1). Range of parameter values are obatined from the references [20,21,25,26,30,31].
    Parameter Interpretation Values Units
    $ \beta $ rate of infection per unit of time by the symptomatic infected varying $ day^{-1} $
    $ p_1 $ reduction factor of infectivity by the $ I_a $ class compared to $ I_s $ class 0.05–0.34 $ - $
    $ p_2 $ reduction factor of infectivity by the $ E $ class compared to $ I_s $ class 0.05–0.34 $ - $
    $ p_3 $ reduction factor of infectivity by the $ Q $ class compared to $ I_s $ class 0.05–0.34 $ - $
    $ p_4 $ reduction factor of infectivity by the $ J $ class compared to $ I_s $ class 0.05–0.34 $ - $
    $ \mu $ rate at which individuals of $ E_1 $ class become infectious exposed 0.25-0.33 $ day^{-1} $
    $ \delta $ rate at which individuals of $ E_2 $ class become infected 0.5–1 $ day^{-1} $
    $ \sigma $ fraction of infectious Exposed population $ E_2 $ that becomes 0–1 $ - $
    Symptomatic infected ($ 0 < \sigma < 1 $)
    $ \eta $ rate of recovery of the asymptomatic infected individuals without 0.1–0.9 $ day^{-1} $
    any medical intervention
    $ \rho_1 $ rate of mortality due to the infection for the individuals of 0.05–0.1 $ day^{-1} $
    infected class with symptom
    $ \zeta_1 $ rate at which the symptomatic infected individuals are quarantined 0.07 $ day^{-1} $
    $ \zeta_2 $ rate of recovery of the symptomatic infected individuals 0.1 $ day^{-1} $
    without any medical intervention
    $ \zeta_3 $ rate of hospitalization of the symptomatic infected individuals 0.14 $ day^{-1} $
    $ \xi_1 $ rate of hospitalization of the quarantined individuals 0.14 $ day^{-1} $
    $ \xi_2 $ rate of recovery from the infection after being quarantined 0.05–0.1 $ day^{-1} $
    $ \rho_2 $ rate of mortality of hospitalized individuals 0.07 $ day^{-1} $
    $ \nu $ rate of transfer of hospitalized individuals to recovered class 0.05 $ day^{-1} $

     | Show Table
    DownLoad: CSV
    Figure 1.  Schematic diagram for the progression of disease described by the model (2.1). Solid arrows represent the transfer from one compartment to another while the dotted line with arrow denote the compartments responsible for disease transmission. Associated rates are mentioned accordingly.

    We have written the basic model with $ \beta $ as constant for the simplicity of forthcoming mathematical calculations. However, for numerical simulations and in order to fit the numerical results with available data [3], we will consider $ \beta\equiv\beta(t) $ as a function of time in order to model the effect of lockdown. In reality the rate of infection is not a constant throughout the epidemic outbreak rather it changes time to time due to the variability in social behavior. Although it is difficult to obtain actual pattern of variation with respect to time but we have considered this variation in order to model the lowering in rate to infection due to the lowering of social contancts during the lockdown period.

    A viable mathematical model for epidemiology must ensure that the solutions of the model under consideration remain non-negative once started from an interior point of the positive cone and remains bounded at all future time. The model considered here is not a completely new rather several close versions are available in various articles on mathematical epidemiology. However, for the completeness we just state the relevant result and a brief outline for the proof is provided at the appendix. For this purpose we consider that the model (2.1) is subjected to the initial conditions $ (S(0), E_1(0), E_2(0), I_a(0), I_s(0), Q(0), J(0), R(0))\in\mathbb{R}^{8}_{+}, $ where positive cone of $ \mathbb{R}^{8} $ is $ \mathbb{R}^{8}_{+} = \{(x_1, ..., x_8):x_i\geq0, i = 1, ..., 8\} $. First we prove that the solution of the system (2.1) remains within $ \mathbb{R}^{8}_{+} $ at all future time once started from a point within $ \mathbb{R}^{8}_{+} $ following the approach outlined in [29].

    Theorem 1. The system (2.1) is invariant in $ \mathbb{R}^{8}_{+} $.

    Proof. See appendix.

    In order to close the model (2.1), we can introduce the compartment for number of COVID related deaths as follows

    $ dDdt=ρ1Is+ρ2J.
    $
    (2.2)

    Now if we write $ N_D = S+E_1+E_2+I_a+I_s+Q+J+R+D $, then from (2.1) and (2.1d), we find

    $ ddtND=0ND=const.
    $
    (2.3)

    With the previous urgument we can prove $ D(t)\geq0 $ and hence $ 0 < N\leq N_D $ implies $ N $ is bounded above, consequently all the constituent variables are also bounded.

    In this section, first we find the basic reproduction number for the model (2.1) in the absence of any control measures, namely, quarantine and hospitalization. For this purpose we assume that the model consists with Susceptible, Exposed, Infected and Recovered class only. The Quarantined and Hospitalized classes are not considered for the time being. Based upon this assumption we can write the following reduced model:

    $ dSdt=βSN(Is+p1Ia+p2E2),
    $
    (2.4a)
    $ dE1dt=βSN(Is+p1Ia+p2E2)μE1,
    $
    (2.4b)
    $ dE2dt=μE1δE2,
    $
    (2.4c)
    $ dIadt=(1σ)δE2ηIa,
    $
    (2.4d)
    $ dIsdt=σδE2(ρ1+ζ2)Is,
    $
    (2.4e)
    $ dRdt=ηIa+ζ2Is,
    $
    (2.4f)

    subjected to non-negative initial conditions $ S(0), E_1(0), E_2(0), I_a(0), I_s(0), R(0)\, \geq\, 0 $. For this model $ N = S+E_1+E_2+I_a+I_s+R $. Here we calculate the basic reproduction number for above model following the next generation matrix approached as introduced in [32]. The disease free equilibrium point is given by $ (N, 0, 0, 0, 0, 0) $, the derivation of basic reproduction number is based upon the stability condition of disease free equilibrium point for the model (2.4). First we rearrange the compartments of the model (2.4) such that first four equations are related to infected compartments from epidemiological point of view (i.e., $ E_1 $, $ E_2 $, $ I_a $ and $ I_s $). Susceptible and recovered compartments will be placed at the end. From (2.4), we can write

    $ ddtX=F1V1,
    $
    (2.5)

    where $ X = [E_1, E_2, I_a, I_s, S, R]^T\equiv[x_1, x_2, x_3, x_4, x_5, x_6]^T $. Here the matrix $ \mathcal{F}_1 $ consists of the terms involved with the appearence of new infection at all the compartments and $ \mathcal{V}_1 $ contains the terms representing entry and exit of all other individuals, rather than direct infection, at all compartments. Explicit expressions for $ \mathcal{F}_1 $ and $ \mathcal{V}_1 $ are given at the appendix.

    For the calculation of basic reproduction number now we need to evaluate two matrices $ F_1 $ and $ V_1 $, which are defined by

    $ F1=[f1ixj]X0,V1=[v1ixj]X0,1i,j4,
    $
    (2.6)

    where $ X_0 = (0, 0, 0, 0, N, 0)^T $. Here we should mention that $ \mathcal{F}_1\, \equiv\, [f_{11}, f_{12}, f_{13}, f_{14}, f_{15}, f_{16}]^T $ and $ \mathcal{V}_1\, \equiv\, [v_{11}, v_{12}, v_{13}, v_{14}, v_{15}, v_{16}]^T $ to avoid any confusion. The largest eigenvalue of the next generation matrix $ F_1V_1^{-1} $ is the basic reproduction number for the model (2.4), (see [32,33]). The matrices $ F_1 $, $ V_1 $ and $ F_1V_1^{-1} $ are given at the appendix.

    The basic reproduction number for the model (2.4) is denoted by $ \mathcal{R}_0^{[1]} $ and is given by

    $ R[1]0=β[p2δ+(1σ)p1η+σρ1+ζ2].
    $
    (2.7)

    Here the superscript ' [1] ' stands for the first model considered in this manuscript, that is for the model (2.1). This basic reproduction number is the sum of three terms, which represents the number of secondary infections produced by an infectious exposed individual, an asymptomatic infected individual, and a symptomatic infected individual respectively. $ \frac{\beta p_2SE_2}{N} $ is the incidence of an exposed individuals who are at the end of the incubation period and can spread the disease. The number of secondary infection produced by an individual of $ E_2 $ compartment in an entirely susceptible population is $ \beta p_2 $ per unit of time. An individual spents an average $ \frac{1}{\delta} $ units of time in $ E_2 $ compartment. Hence the number of secondary infection produced by an individual of $ E_2 $ compartment is $ \frac{\beta p_2}{\delta} $. The number of secondary infections produced by the individuals of $ I_a $ and $ I_s $ compartments in an entirely susceptible population, per unit of time, are $ \beta (1-\sigma)p_1 $ and $ \beta\sigma $ respectively. The average time units spend by the asymptomatic and symptomatic infectious individuals with their respective compartments are $ \frac{1}{\eta} $ and $ \frac{1}{\rho_1+\zeta_2} $. Hence the number of secondary infection produced by the individuals of $ I_a $ and $ I_s $ comparments are $ \frac{\beta(1-\sigma)p_1}{\eta} $ and $ \frac{\beta\sigma}{\rho_1+\zeta_2} $ respectively.

    Henceforth we follow the similar notation and approach to calculate other relevant reproduction numbers without providing detailed description, the expressions for large matrices are provided at the appendix. Now we calculate the controlled reproduction number for the model (2.1).

    The model (2.1) can be written as follows

    $ ddtX=F2V2,
    $

    $ X = [E_1, E_2, I_a, I_s, Q, J, S, R]^T\equiv[x_1, x_2, x_3, x_4, x_5, x_6, x_7, x_8]^T $ with six compartments contribute to the propagation of infection. We can define following two matrices

    $ F2=[f2ixj]X0,V2=[v2ixj]X0,1i,j6,
    $
    (2.8)

    where $ X_0 = (0, 0, 0, 0, 0, 0, N, 0) $.

    The controlled reproduction number for the model (2.1) is given by

    $ R[1]c=β[p2δ+p1(1σ)η+σρ1+ζ1+ζ2+ζ3+p3ζ1σ(ρ1+ζ1+ζ2+ζ3)(ξ1+ξ2)+p4σζ3(ρ1+ζ1+ζ2+ζ3)(ρ2+ν)+p4σξ1ζ1(ρ1+ζ1+ζ2+ζ3)(ξ1+ξ2)(ρ2+ν)].
    $
    (2.9)

    The different terms involved with $ \mathcal{R}_c^{[1]} $ can be explained in a similar way as given above, interested readers can see [34,35] for detailed discussion. It is important to mention here that substituting $ \zeta_1 = \zeta_3 = 0 $ we can find the basic reproduction number $ \mathcal{R}_0^{[1]} $ from the controlled reproduction number $ \mathcal{R}_c^{[1]} $.

    In order to determine the final size of the epidemic, we find three relevant quantites $ S_f $, $ R_f $ and $ D_f $. Here $ S_f $ is the final size of the susceptible compartment at the end of outbreak, theoretically it is defined by $ \lim_{t\rightarrow\infty}S(t)\, = \, S_f $ [34,35]. Let $ t_f $ denotes the time at which the number of infected is zero that is at the end of epidemic outbreak and consequently $ S_f $, $ R_f $ and $ D_f $ can be considered as the values of $ S(t) $, $ R(t) $ and $ D(t) $ at $ t\, = \, t_f $. First we calculate the final size of the susceptible compartment that is $ S_f $. We integrate the equation for $ S $ (i.e., (2.1a)) between $ t = 0 $ to $ t = t_f(\, = \, \infty) $ and find

    $ lnS0Sf=βNtf0(Is+p1Ia+p2E2+p3Q+p4J)dt,
    $
    (2.10)

    where $ S_0 $ and $ S_f $ denotes initial and final size of the susceptible population.

    Now we assume that the model (2.1) is subjected to the initial condition that $ S_0, E_{10} > 0 $ and all other components are absent at the initial time point $ t = 0 $. Consequently $ S_0+E_{10} = N $. Now integrating (2.1c) between $ t = 0 $ and $ t = t_f $ and with the assumption that $ E_{20} = E_{2f} = 0 $, we find

    $ tf0E2dt=μδtf0E1dt.
    $
    (2.11)

    Similarly from (2.1d) we find the following result,

    $ tf0Iadt=(1σ)δηtf0E2dt=μ(1σ)ηtf0E1dt.
    $
    (2.12)

    Proceeding in a similar way, from Eqs (2.1e)–(2.1g) and using above results we find,

    $ tf0Isdt=μσρ1+ζ1+ζ2+ζ3tf0E1dt,
    $
    (2.13)
    $ tf0Qdt=ζ1μσ(ξ1+ξ2)(ρ1+ζ1+ζ2+ζ3)tf0E1dt,
    $
    (2.14)

    and

    $ tf0Jdt=ζ3ρ2+νtf0Isdt+ξ1ρ2+νtf0Qdt,=μσ(ρ2+ν)(ρ1+ζ1+ζ2+ζ3)[ζ3+ξ1ζ1ξ1+ξ2]tf0E1dt.
    $
    (2.15)

    Now if we add two equations (2.1a) and (2.1b), and then integrating we find

    $ NSf=μtf0E1dt,
    $
    (2.16)

    where $ S_0 = N $ and we assume $ E_{10}, \, E_{1f} = 0 $. Now using the results (2.11)–(2.15), from (2.10) we find

    $ lnS0Sf=βN[p2δ+p1(1σ)η+σρ1+ζ1+ζ2+ζ3(1+p3ζ1ξ1+ξ2)p3σ(ρ2+ν)(ρ1+ζ1+ζ2+ζ3)(ζ3+ξ1ζ1ξ1+ξ2)]μtf0E1dt.
    $
    (2.17)

    Finally using (2.16) and the expression for $ \mathcal{R}_c^{[1]} $, we obtain the final size of the epidemic as follows

    $ lnS0Sf=R[1]c(1SfN).
    $
    (2.18)

    At the begining of the epidemic without any loss of generality we can assume that the entire population is susceptible and hence $ N = S_0 $. Using $ \frac{S_f}{S_0}\equiv\frac{S_f}{N} = x $ in above equation we get the following equation

    $ Φ(x)lnx+R[1]c(1x)=0.
    $
    (2.19)

    This equation possesses a solution within the interval $ (0, 1) $ when $ \mathcal{R}_c^{[1]} > 1 $ and root of the equation $ \Phi(x) = 0 $ gives the final size of the epidemic. On the other hand the question of final size of the epidemic will not arise in case of $ \mathcal{R}_c^{[1]}\leq1 $ as there is no root of the equation $ \Phi(x) = 0 $ within $ (0, 1) $. This claim can be verified from the Figure 2.

    Figure 2.  Plot of $ \Phi(x) $ for three different values of $ \mathcal{R}_c^{[1]} $: $ \mathcal{R}_c^{[1]} = 2 $ (blue), $ \mathcal{R}_c^{[1]} = 1 $ (red) and $ \mathcal{R}_c^{[1]} = 0.6 $ (yellow).

    To understand the final size of the deceased compartment we need to calculate $ D_f $ and $ R_f $. Clearly $ R_0 = 0 $ and $ D_0 = 0 $, hence by integrating the equations for recovered and deceased compartments between $ t = 0 $ to $ t = t_f $ we find

    $ Rf=tf0(ηIa+ζ2Is+ξ2Q+νJ)dt,
    $
    (2.20)

    and

    $ Df=tf0(ρ1Is+ρ2J)dt.
    $
    (2.21)

    Using the results (2.12)–(2.15), we find from above two equations,

    $ Rf=[μ(1σ)+μσρ1+ζ1+ζ2+ζ3(ζ2+ξ2ζ1ξ1+ξ2+νζ3ρ2+ν+νξ1ζ1(ρ2+ν)(ξ1+ξ2))]tf0E1dt,
    $
    (2.22)

    and

    $ Df=[μσρ1+ζ1+ζ2+ζ3(ρ1+ρ2ρ2+ν(ζ3+ξ1ζ1ξ1+ξ2))]tf0E1dt.
    $
    (2.23)

    If we define

    $ ω=μ(1σ)+μσρ1+ζ1+ζ2+ζ3(ζ2+ξ2ζ1ξ1+ξ2+νζ3ρ2+ν+νξ1ζ1(ρ2+ν)(ξ1+ξ2))μσρ1+ζ1+ζ2+ζ3(ρ1+ρ2ρ2+ν(ζ3+ξ1ζ1ξ1+ξ2)),
    $
    (2.24)

    then

    $ RfDf=ω.
    $
    (2.25)

    In the following, we have divided the susceptible population ($ S $), Exposed population (cannot spread infection ($ E_1 $) and can spread infection ($ E_2 $)), asymptomatic infective ($ I_a $) and symptomatic infective ($ I_s $) of model (2.1) into two subclasses, namely $ S_1 $, $ S_2 $, $ E_{11} $, $ E_{21} $, $ E_{12} $, $ E_{22} $, $ I_{a_1} $, $ I_{a_2} $, $ I_{s_1} $, $ I_{s_2} $ respectively based on their classification or behaviour which is directly responsible for the alteration of rate of disease spread. The classification or division into two different groups may be due to the different age groups, different implementation of distancing measures, proper and improper use of face mask and so on, related to the human behaviours. The total population size can be written as $ N\, = \, S_1+S_2+E_{11}+E_{21}+E_{12}+E_{22}+I_{a_1}+I_{a_2}+I_{s_1}+I_{s_2}+Q+J+R $ and $ N $ is not fixed since deceased compartment is not included in the model. The assumptions for the extended model formulation are given as follows:

    Susceptible population $ S(t) $: This subpopulation is divided into two subclasses $ S_1 $ and $ S_2 $. The population in the compartment $ S_1 $ will decrease after an infection due to the interaction with an symptomatic infected individual $ (I_{s_1}, \, I_{s_2}) $ with transmission coefficients $ \beta_{11}I_{s_1}/N $, $ \beta_{12}I_{s_2}/N $ respectively, asymptomatic infected individual $ (I_{a_1}, \, I_{a_2}) $ with transmission coefficients $ \beta_{11}p_{11}I_{a_1}/N $, $ \beta_{12}p_{21}I_{a_2}/N $ respectively, infectious exposed individual $ (E_{12}, \, E_{22}) $ with transmission coefficients $ \beta_{11}p_{12}E_{12}/N $, $ \beta_{12}p_{22}E_{22}/N $ respectively, quarantine $ (Q) $ with transmission coefficients $ \beta_Q Q/N $ or hospitalised one $ (J) $ with transmission coefficients $ \beta_J J/N $. Here $ \beta_{11} $, $ \beta_{12} $ are rates of infection per unit of time by the symptomatic infected $ I_{s_1} $, $ I_{s_2} $ respectively, $ \beta_Q $, $ \beta_J $ are rates of infection per unit of time by the quarantined and hospitalized population $ (Q, J) $ respectively, $ p_{11} $, $ p_{12} $, $ p_{21} $ and $ p_{22} $ are the reduction factor of infectivity by $ I_{a_1} $, $ E_{12} $, $ I_{a_2} $ and $ E_{22} $ respectively compared to $ I_{s_1} $ and $ I_{s_2} $ and satisfy the restriction $ 0\leq p_{ij} < 1 $, $ i, j = 1, 2 $. $ S_2 $ will decrease after an infection due to the interaction with an symptomatic infected individual $ (I_{s_1}, \, I_{s_2}) $ with transmission coefficients $ \beta_{21}I_{s_1}/N $, $ \beta_{22}I_{s_2}/N $ respectively, asymptomatic infected individual $ (I_{a_1}, \, I_{a_2}) $ with transmission coefficients $ \beta_{21}p_{31}I_{a_1}/N $, $ \beta_{22}p_{41}I_{a_2}/N $ respectively, infectious exposed individual $ (E_{12}, \, E_{22}) $ with transmission coefficients $ \beta_{21}p_{32}E_{12}/N $, $ \beta_{22}p_{42}E_{22}/N $ respectively, quarantine $ (Q) $ with transmission coefficients $ \beta_Q Q/N $ or hospitalised one $ (J) $ with transmission coefficients $ \beta_J J/N $. Here $ \beta_{21} $, $ \beta_{22} $ are rates of infection per unit of time by the symptomatic infected $ I_{s_1} $, $ I_{s_2} $ respectively, $ \beta_Q $, $ \beta_J $ are rates of infection per unit of time by the quarantined and hospitalized population $ (Q, \, J) $ respectively, $ p_{31} $, $ p_{32} $, $ p_{41} $ and $ p_{42} $ are the reduction factor of infectivity by $ I_{a_1} $, $ E_{12} $, $ I_{a_2} $ and $ E_{22} $ respectively compared to $ I_{s_1} $ and $ I_{s_2} $ and satisfy the restriction $ 0\leq p_{ij} < 1 $, $ i = 3, 4, j = 1, 2 $. The rate of change of the susceptible population is expressed in the following two equations:

    $ dS1dt=S1N[β11(Is1+p11Ia1+p12E12)+β12(Is2+p21Ia2+p22E22)+βQQ+βJJ],dS2dt=S2N[β21(Is1+p31Ia1+p32E12)+β22(Is2+p41Ia2+p42E22)+βQQ+βJJ].
    $

    The rate of change of two groups of the exposed compartments, who are not infectious, is described by the follwoing two equations

    $ \frac{dE_{11}}{dt}\, = \, \frac{S_1}{N}\left[\beta_{11} (I_{s_1}+p_{11}I_{a_1}+p_{12}E_{12} )+\beta_{12}(I_{s_2}+p_{21}I_{a_2}+p_{22}E_{22})+\beta_Q Q+\beta_J J\right]-\mu_1 E_{11}, $
    $ \frac{dE_{21}}{dt}\, = \, \frac{S_2}{N}\left[\beta_{21}(I_{s_1}+p_{31}I_{a_1}+p_{32}E_{12})+\beta_{22}(I_{s_2}+p_{41}I_{a_2}+p_{42}E_{22})+\beta_Q Q+\beta_J J\right]-\mu_2 E_{21}, $

    where $ \mu_1 $ and $ \mu_2 $ are the rates at which $ E_{11} $ and $ E_{21} $ progress to the infectious exposed compartments $ E_{12} $ and $ E_{22} $ respectively. The infectious exposed individuals leave the respective classes at rates $ \delta_1 $ and $ \delta_2 $, hence their rate of change with respect to time is given by

    $ \frac{dE_{12}}{dt}\, = \, \mu_1 E_{11}-\delta_1 E_{12}, $
    $ \frac{dE_{22}}{dt}\, = \, \mu_2 E_{21}-\delta_2 E_{22}. $

    The governing equations for the two groups of asymptomatic and symptomatic infected classes are given as follows:

    $ \frac{dI_{a_1}}{dt}\, = \, (1-\sigma_1)\delta_1 E_{12}-\eta_1 I_{a_1}, $
    $ \frac{dI_{a_2}}{dt}\, = \, (1-\sigma_2)\delta_2 E_{22}-\eta_2 I_{a_2}, $
    $ \frac{dI_{s_1}}{dt}\, = \, \sigma_1 \delta_1 E_{12}-(\rho_{11}+\zeta_{11}+\zeta_{12}+\zeta_{13})I_{s_1}, $
    $ \frac{dI_{s_2}}{dt}\, = \, \sigma_2 \delta_2 E_{22}-(\rho_{21}+\zeta_{21}+\zeta_{22}+\zeta_{23})I_{s_2}, $

    where the parameters $ \sigma_j $, $ \rho_{j1} $, $ \zeta_{j1} $, $ \zeta_{j2} $ and $ \zeta_{j3} $ ($ j = 1, 2 $) have the similar interpretation as that of $ \sigma $, $ \rho_1 $, $ \zeta_1 $, $ \zeta_2 $ and $ \zeta_3 $ as described in Table 1 for model (2.1).

    Distinction for quarantined, hospitalized and recovered compartments are not required as first two groups are under indirect and direct medical interventions and recovered individuals have no direct role to play with the disease spread. Finally including the governing equations for quarantined, hospitalized and recovered compartments and using previous equations we get the final two-group infection model as follows,

    $ dS1dt=S1N[β11(Is1+p11Ia1+p12E12)+β12(Is2+p21Ia2+p22E22)+βQQ+βJJ],
    $
    (3.1a)
    $ dS2dt=S2N[β21(Is1+p31Ia1+p32E12)+β22(Is2+p41Ia2+p42E22)+βQQ+βJJ],
    $
    (3.1b)
    $ dE11dt=S1N[β11(Is1+p11Ia1+p12E12)+β12(Is2+p21Ia2+p22E22)+βQQ+βJJ]μ1E11,
    $
    (3.1c)
    $ dE21dt=S2N[β21(Is1+p31Ia1+p32E12)+β22(Is2+p41Ia2+p42E22)+βQQ+βJJ]μ2E21,
    $
    (3.1d)
    $ dE12dt=μ1E11δ1E12,
    $
    (3.1e)
    $ dE22dt=μ2E21δ2E22,
    $
    (3.1f)
    $ dIa1dt=(1σ1)δ1E12η1Ia1,
    $
    (3.1g)
    $ dIa2dt=(1σ2)δ2E22η2Ia2,
    $
    (3.1h)
    $ dIs1dt=σ1δ1E12(ρ11+ζ11+ζ12+ζ13)Is1,
    $
    (3.1i)
    $ dIs2dt=σ2δ2E22(ρ21+ζ21+ζ22+ζ23)Is2,
    $
    (3.1j)
    $ dQdt=ζ11Is1+ζ21Is2(ξ1+ξ2)Q,
    $
    (3.1k)
    $ dJdt=ζ12Is1+ζ22Is2+ξ1Q(ρ2+ν)J,
    $
    (3.1l)
    $ dRdt=η1Ia1+η2Ia2+ζ13Is1+ζ23Is2+ξ2Q+νJ.
    $
    (3.1m)

    Here $ \rho_{11} $, $ \rho_{21} $, $ \xi_1 $ and $ \rho_2 $ are the disease related death rates for the compartments $ I_{s_1} $, $ I_{s_2} $, $ Q $ and $ J $ respectively. A schematic diagram is presented in Figure 3 without the rate constants in order to avoid clumsiness.

    Figure 3.  Schematic diagram for the disease progression described by the model (3.1). Solid arrows represent the transfer from one compartment to another while the dotted line with arrow denote the compartments responsible for disease transmission.

    Before analyzing the above model, here we explain how the model (2.1) can be derived from the model (3.1) under suitable assumptions. For this purpose first adding the Eqs (3.1e) and (3.1f), we find

    $ ddt(E12+E22)=(μ1E11+μ2E21)(δ1E12+δ2E22).
    $

    If we assume $ \mu_1 = \mu_2 = \mu $ and $ \delta_1 = \delta_2 = \delta $, then we find

    $ ddt(E12+E22)=μ(E11+E21)δ(E12+E22),
    $

    which is Eq (2.1c) if we write $ (E_{11}+E_{21}) = E_1 $ and $ (E_{12}+E_{22}) = E_2 $ respectively.

    Similarly, with the previous assumptions on parameters and variables, and additional assumptions $ \sigma_1 = \sigma_2 = \sigma $, $ \eta_1 = \eta_2 = \eta $ and $ I_{a_1}+I_{a_2} = I_a $, we can derive (2.1d) by adding (3.1g) and (3.1h). We can also derive (2.1e) from the Eqs (3.1i) and (3.1j) using the similar procedure.

    Derivation of Eq (2.1a) by adding Eqs (3.1a) and (3.1b) is little bit tricky. Adding (3.1a) and (3.1b), and rearranging the terms, we can write

    $ ddt(S1+S2)=S1N(β11Is1+β12Is2)S2N(β21Is1+β22Is2)S1N(β11p11Ia1+β12p21Ia2)S2N(β21p31Ia1+β22p41Ia2)S1N(β11p12E12+β12p22E22)S2N(β11p12E12+β12p22E22)S1+S2NβQQS1+S2NβJJ.
    $

    Firstly, if we assume $ \beta_{11} = \beta_{12} = \beta_{21} = \beta_{22} = \beta $, $ \beta_Q = p_3\beta $, $ \beta_J = p_4\beta $, then we can write

    $ ddt(S1+S2)=β(S1+S2)N(Is1+Is2)βS1N(p11Ia1+p21Ia2)βS2N(p31Ia1+p41Ia2)βS1N(p12E12+p22E22)βS2N(p12E12+p22E22)β(S1+S2)N(p3Q+p4J).
    $

    Further if we assume $ p_{j1} = p_1 $, $ p_{j2} = p_2 $, $ j = 1, 2, 3, 4 $, we can write from above equation

    $ ddt(S1+S2)=β(S1+S2)N(Is1+Is2)βp1(S1+S2)N(Ia1+Ia2)βp2(S1+S2)N(E12+E22)β(S1+S2)N(p3Q+p4J).
    $

    Finally writing $ S_1+S_2 = S $, and using previous assumptions related to $ E_2 $, $ I_a $ and $ I_s $, we can write above equation as

    $ dSdt=βSN(Is+p1Ia+p2E2+p3Q+p4J).
    $

    With the other necessary assumptions on the remaining parameters and variables we can derive the model (2.1) from (3.1). Once the two group of individiuals are non-distinguishable, then the model (2.1) results in from the model (3.1).

    For simplicity of forthcoming calculations, we can write the first two Eqs (3.1a)–(3.1b) into the matrix form as follows:

    $ ddtˉS=1NdiagˉS[BˉIs+B1ˉIa+B2ˉE2+BQQ+BJJ],
    $
    (3.2)

    where

    $ ˉS=[S1S2],ˉIs=[Is1Is2],ˉE2=[E12E22],diagˉS=[S100S2],
    $
    (3.3)

    and

    $ B=[β11β12β21β22],B1=[β11p11β12p21β21p31β22p41],B2=[β11p12β12p22β21p32β22p42],BQ=[βQβQ],BJ=[βJβJ].
    $
    (3.4)

    Using above approach, we can write (3.1c)– (3.1d) into a compact form as follows

    $ ddtˉE1=1NdiagˉS[BˉIs+B1ˉIa+B2ˉE2+BQQ+BJJ]diag(μ1,μ2)ˉE1,
    $
    (3.5)

    where

    $ ˉE1=[E11E21],diag(μ1,μ2)=[μ100μ2].
    $
    (3.6)

    Similarly, Eqs (3.1e)–(3.1f), (3.1g)–(3.1h) and (3.1i)–(3.1j) can be written as

    $ ddtˉE2=diag(μ1,μ2)ˉE1diag(δ1,δ2)ˉE2,
    $
    (3.7)
    $ ddtˉIa=diag((1σ1)δ1,(1σ2)δ2)ˉE2diag(η1,η2)ˉIa,
    $
    (3.8)

    and

    $ ddtˉIs=diag(σ1δ1,σ2δ2)ˉE2diag(ρ11+ζ11+ζ12+ζ13,ρ21+ζ21+ζ22+ζ23)ˉIs,
    $
    (3.9)

    respectively.

    In order to calculate the controlled reproduction number for the model (3.1), we follow the similar approach as we have used for the model (2.1). Without giving much description, here we just define the relevant matrices as follows,

    $ F3=[S1N(β11(Is1+p11Ia1+p12E12)+β12(Is2+p21Ia2+p22E22)+βQQ+βJJ)S2N(β21(Is1+p31Ia1+p32E12)+β22(Is2+p41Ia2+p42E22)+βQQ+βJJ)θ8×1],
    $
    (3.10)
    $ V3=[μ1E11μ2E21δ1E12μ1E11δ2E22μ2E21η1Ia1(1σ1)δ1E12η2Ia2(1σ2)δ2E22(ρ11+ζ11+ζ12+ζ13)Is1σ1δ1E12(ρ21+ζ21+ζ22+ζ23)Is2σ2δ2E22(ξ1+ξ2)Q(ζ11Is1+ζ21Is2)(ρ2+ν)Jζ12Is1ζ22Is2ξ1Q].
    $
    (3.11)

    Evaluating the Jacobian matrices, at $ (N_1, N_2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0) $ (the disease free equilibrium point), corresponding to $ \mathcal{F}_3 $ and $ \mathcal{V}_3 $, we can find $ F_3 $ and $ V_3 $, their explicit expressions are provided at the appendix. The controlled reproduction number is the largest eigenvalue of the matrix $ F_3V_3^{-1} $.

    In terms of the matrices introduced above, we can rewrite $ F_3 $ and $ V_3 $ as partitioned matrices analogous to the matrices $ F_2 $ and $ V_2 $ as in the previous section. $ F_3 $ and $ V_3 $ can be rewritten as

    $ F3=[θ2×2B2NNB1NNBNNBQNNBJNNθ2×2θ2×2θ2×2θ2×2θ2×1θ2×1θ2×2θ2×2θ2×2θ2×2θ2×1θ2×1θ2×2θ2×2θ2×2θ2×2θ2×1θ2×1θ1×2θ1×2θ1×2θ1×2θ1×1θ1×1θ1×2θ1×2θ1×2θ1×2θ1×1θ1×1],
    $
    (3.12)
    $ V3=[diag(μ1,μ2)θ2×2θ2×2θ2×2θ2×1θ2×1diag(μ1,μ2)diag(δ1,δ2)θ2×2θ2×2θ2×1θ2×1θ2×2diag((1σ1)δ1,(1σ2)δ2)diag(η1,η2)θ2×2θ2×1θ2×1θ2×2diag(σ1δ1,σ2δ2)θ2×2diag(α1,α2)θ2×1θ2×1θ1×2θ1×2θ1×2[ζ11ζ21]ξ1+ξ20θ1×2θ1×2θ1×2[ζ12ζ22]ξ1ρ2+ν],
    $
    (3.13)

    where

    $ BN=[β11N1β12N1β21N2β22N2],B1N=[β11p11N1β12p21N1β21p31N2β22p41N2],B2N=[β11p12N1β12p22N1β21p32N2β22p42N2],
    $
    (3.14)
    $ BQN=[βQN1βQN2],BJN=[βJN1βJN2].
    $
    (3.15)

    Two constants $ \alpha_1 $ and $ \alpha_2 $ are defined by

    $ α1=ρ11+ζ11+ζ12+ζ13,α2=ρ21+ζ21+ζ22+ζ23.
    $
    (3.16)

    The matrix $ V_3^{-1} $ is a lower triangular partitioned matrix. Based upon the non-zero entries of $ F_3 $, we need the elements in first two columns of the matrix $ V_3^{-1} $ in order to calculate the controlled reproduction number. If we write $ V_3^{-1} $ in the following form

    $ V13=[Ψ10×2Ω10×8],
    $
    (3.17)

    where

    $ Ψ10×2=[(diag(μ1,μ2))1(diag(δ1,δ2))1diag(1σ1η1,1σ2η2)diag(σ1α1,σ2α2)(σ1ζ11(ξ1+ξ2)α1σ2ζ21(ξ1+ξ2)α2)(σ1(ξ1(ζ11+ζ12)+ζ12ξ2)α1(ξ1+ξ2)(ρ2+ν)σ2(ξ1(ζ21+ζ22)+ζ22ξ2)α2(ξ1+ξ2)(ρ2+ν))].
    $
    (3.18)

    Once we calculate the matrix $ F_3V_3^{-1} $, it comes out to be a matrix of following form

    $ F3V13=[Γ2×10θ8×10],
    $
    (3.19)

    and hence the non-zero eigenvalues can be determined from the first $ 2\times2 $ block of the block matrix $ \Gamma_{2\times10} $ involved with $ F_3V_3^{-1} $. The entries of the first $ 2\times2 $ block can be calculated as follows,

    $ [γ11γ12γ21γ22]=1N[(diag(δ1,δ2))1B2N+diag(1σ1η1,1σ2η2)B1N+diag(σ1α1,σ2α2)BN+(σ1ζ11(ξ1+ξ2)α1σ2ζ21(ξ1+ξ2)α2)BQN+(σ1(ξ1(ζ11+ζ12)+ζ12ξ2)α1(ξ1+ξ2)(ρ2+ν)σ2(ξ1(ζ21+ζ22)+ζ22ξ2)α2(ξ1+ξ2)(ρ2+ν))BJN].
    $
    (3.20)

    Explicit expressions for $ \gamma_{ij} $, $ (i, j = 1, 2) $ are given by

    $ γ11=N1N[β11p12δ1+β11p11(1σ1)η1+β11σ1α1+βQζ11σ1(ξ1+ξ2)α1+βJσ1(ξ1(ζ11+ζ12)+ζ12ξ2)α1(ξ1+ξ2)(ρ2+ν)],
    $
    (3.21a)
    $ γ12=N1N[β12p22δ2+β11p21(1σ2)η2+β12σ2α2+βQζ21σ2(ξ1+ξ2)α2+βJσ2(ξ1(ζ21+ζ22)+ζ22ξ2)α2(ξ1+ξ2)(ρ2+ν)],
    $
    (3.21b)
    $ γ21=N2N[β21p32δ1+β21p31(1σ1)η1+β21σ1α1+βQζ11σ1(ξ1+ξ2)α1+βJσ1(ξ1(ζ11+ζ12)+ζ12ξ2)α1(ξ1+ξ2)(ρ2+ν)],
    $
    (3.21c)
    $ γ22=N2N[β22p42δ2+β22p41(1σ2)η2+β12σ2α2+βQζ21σ2(ξ1+ξ2)α2+βJσ2(ξ1(ζ21+ζ22)+ζ22ξ2)α2(ξ1+ξ2)(ρ2+ν)].
    $
    (3.21d)

    The matrix $ F_3V_3^{-1} $ has at most two non-zero eigenvalues and eight zero eigenvalues. The maximum positive eigenvalue of the matrix $ F_3V_3^{-1} $ is the controlled reproduction number for the model (3.1). As a matter of fact the controlled reproduction number for the model (3.1) is the largest eigenvalue of the matrix $ [\gamma_{ij}]_{2\times2} $ and is given by

    $ R[2]c=γ11+γ22+(γ11γ22)2+4γ12γ212.
    $
    (3.22)

    Here the superscript '[2]' stands for the second mathematical model considered in this manuscript, that is for the model (3.1).

    Derivation of final size of the epidemic is tedious but can be obtained through step by step calculations. The final sizes, for different compartments, can be determined in a similar manner as we have done in the previous section. From (3.1a) & (3.1b), integrating between the limits $ t = 0 $ and $ t = t_f(\, = \, \infty) $, we find

    $ lnS10S1f=1Ntf0[β11(Is1+p11Ia1+p12E12)+β12(Is2+p21Ia2+p22E22)+βQQ+βJJ]dt,
    $
    (3.23)
    $ lnS20S2f=1Ntf0[β21(Is1+p31Ia1+p32E12)+β22(Is2+p41Ia2+p42E22)+βQQ+βJJ]dt,
    $
    (3.24)

    where $ S_{j0} $ and $ S_{jf} $ denote initial and final size of the $ j $-th susceptible class, $ j = 1, 2 $. Now we assume that the model (3.1) is subjected to the initial conditions such that $ S_{10}, S_{20}, E_{110}, E_{210} > 0 $ and all other components are absent at the initial time point $ t = 0 $. Consequently $ S_{10}+S_{20}+E_{110}+E_{210} = N $. Now integrating (3.1e), (3.1f) between $ t = 0 $ and $ t = t_f $ and with the assumption that $ E_{120} = E_{220} = E_{12f} = E_{22f} = 0 $, we find

    $ tf0E12dt=μ1δ1tf0E11dt,tf0E22dt=μ2δ2tf0E21dt.
    $
    (3.25)

    Next integrating (3.1g), (3.1h) between $ t = 0 $ and $ t = t_f $ and with the assumption that $ I_{a_10} = I_{a_20} = I_{a_1f} = I_{a_2f} = 0 $, using (3.25) we find

    $ tf0Ia1dt=μ1(1σ1)η1tf0E11dt,tf0Ia2dt=μ2(1σ2)η2tf0E21dt.
    $
    (3.26)

    Proceeding in a similar way and using the results in (3.26), we get from (3.1i), (3.1j)

    $ tf0Is1dt=μ1σ1α1tf0E11dt,tf0Is2dt=μ2σ2α2tf0E21dt,
    $
    (3.27)

    where $ \alpha_1 $ and $ \alpha_2 $ are defined in (3.16). Using the above result, from (3.1k) we get

    $ tf0Qdt=1ξ1+ξ2[μ1σ1ζ11α1tf0E11dt+μ2σ2ζ21α2tf0E21dt].
    $
    (3.28)

    Finally, integrating (3.1l) between $ t = 0 $ and $ t = t_f $ and using $ J_0 = 0 = J_f $, we can write

    $ tf0Jdt=1ρ2+ν[ζ12tf0Is1dt+ζ22tf0Is2dt+ξ1tf0Qdt].
    $
    (3.29)

    Using the results from (3.27) and (3.28), we can express the $ \int_0^{t_f}Jdt $ in terms of $ \int_0^{t_f}E_{11}dt $ and $ \int_0^{t_f}E_{21}dt $. Now adding the equations (3.1a) and (3.1c) and then integrating between $ t = 0 $ and $ t = t_f $, we find

    $ N1S1f=μ1tf0E11dt,
    $
    (3.30)

    where we have used $ E_{110} = E_{11f} = 0 $ and $ S_{10} = N_1 $. Similarly, adding the Eqs (3.1b) and (3.1d) and following the same approach, we can find

    $ N2S2f=μ2tf0E21dt.
    $
    (3.31)

    Now using the results (3.25)–(3.29), we get from (3.23),

    $ lnS10S1f=1N[μ1Δ11tf0E11dt+μ2Δ12tf0E21dt],
    $
    (3.32)

    where

    $ Δ11=β11(σ1α1+p11(1σ1)η1+p12δ1)+βQσ1ζ11α1(ξ1+ξ2)+βJσ1α1(ρ2+ν)(ζ12+ξ1ζ11ξ1+ξ2),
    $
    (3.33)
    $ Δ12=β12(σ2α2+p21(1σ2)η2+p22δ2)+βQσ2ζ21α2(ξ1+ξ2)+βJσ2α2(ρ2+ν)(ζ22+ξ1ζ21ξ1+ξ2).
    $
    (3.34)

    Proceeding in a similar way, from (3.24), we can derive

    $ lnS20S2f=1N[μ1Δ21tf0E11dt+μ2Δ22tf0E21dt],
    $
    (3.35)

    where

    $ Δ21=β21(σ1α1+β21p31(1σ1)η1+p32δ1)+βQσ1ζ11α1(ξ1+ξ2)+βJσ1α1(ρ2+ν)(ζ12+ξ1ζ11ξ1+ξ2),
    $
    (3.36)
    $ Δ22=β22(σ2α2+p41(1σ2)η2+p42δ2)+βQσ2ζ21α2(ξ1+ξ2)+βJσ2α2(ρ2+ν)(ζ22+ξ1ζ21(ξ1+ξ2)).
    $
    (3.37)

    Eliminating $ \int_0^{t_f}E_{11}dt $ and $ \int_0^{t_f}E_{21}dt $ between (3.30), (3.31) and (3.35), we find the following two equations

    $ lnS10S1f=1N[Δ11(N1S1f)+Δ12(N2S2f)],
    $
    (3.38)
    $ lnS20S2f=1N[Δ21(N1S1f)+Δ22(N2S2f)].
    $
    (3.39)

    Without any loss of generality, writing $ S_{10} = N_1 $ and $ S_{20} = N_2 $ and introducing the notations $ \frac{S_{1f}}{N_1} = x $, $ \frac{S_{2f}}{N_2} = y $ we get from above system equations

    $ y=1φ12lnx+φ11φ12(1x)+1Φ1(x),
    $
    (3.40a)
    $ x=1φ21lny+φ22φ21(1y)+1Φ2(y),
    $
    (3.40b)

    where

    $ \varphi_{ij}\, = \, \frac{N_j}{N}\Delta_{ij}, \, \, i, \, j\, = \, 1, \, 2. $

    It is interesting to note that the following two matrices are similar matrices,

    $ P=[γ11γ12γ21γ22],Q=[φ11φ12φ21φ22].
    $
    (3.41)

    If we define a diagonal matrix

    $ D=[N1N00N2N],
    $
    (3.42)

    then we can verify that

    $ Q=D1PD.
    $
    (3.43)

    Entries of both the matrices $ P $ and $ Q $ are positive and as they are similar, the spectrum of two matrices are same. Hence the largest eigenvalue of the matrix $ Q $ is equal to the largest eigenvalue of the matrix $ P $ that is equal to $ \mathcal{R}_c^{[2]} $.

    The existence of final size of the epidemic depends upon the existence of a point of intersection between two curves $ y = \Phi_1(x) $ and $ x = \Phi_2(y) $ within the unit square $ [0, 1]\times[0, 1] $. Existence of such point of intersection follows from the Th. 1 in [36]. The two curves $ y = \Phi_1(x) $ and $ x = \Phi_2(y) $ intersect each other at a point $ (\bar{x}, \bar{y}) $, $ 0 < \bar{x}, \bar{y} < 1 $ whenever $ \mathcal{R}_c^{[2]} > 1 $. Knowing the values of $ \bar{x} $, $ \bar{y} $ we can determine the final sizes $ S_{1f} $ and $ S_{2f} $.

    In this section we present the numerical simulation results for two models (2.1) and (3.1) considered in this work. First we present the simulation results for the model (2.1) by fitting the numerical simulation results with the COVID-19 data for Germany as an illustrative example. All the data used in this manuscript are taken from [3]. In order to ensure that the obtained result and the validity of the model is not country specific rather it can be matched with the data for other countries. Fitting of the data for Italy, UK and Spain are provided at the appendix.

    The sensitivity of various parameters involved with the model (2.1) plays an important role behind numerical simulations. It would be quite lengthy calculations if we want to perform the same for the model (3.1) and hence we have restricted ourselves to the first model only. For numerical simulations and fitting with the data, we have considered the rate of infection as a function of time and hence some of the estimated parameters do not remain fixed throughout the simulation and hence we have presented the sensivity indices with respect to the estimated parameter values.

    The sensitivity analysis for the endemic threshold (the controlled reproduction number $ \mathcal{R}_c^{[1]} $) in Eq (2.9) tells us how important each parameter is to disease transmission. It is used to understand parameters that have a high impact on the threshold $ \mathcal{R}_c^{[1]} $ and should be targeted by intervention strategies. More precisely, sensitivity indices’ allows us to measure the relative change in a variable when a parameter changes. For that purpose, we use the normalized forward sensitivity index of a variable with respect to a given parameter, which is defined as the ratio of the relative change in the variable to the relative change in the parameter. If such variable is differentiable with respect to the parameter, then the sensitivity index is defined as follows.

    The normalized forward sensitivity index of $ \mathcal{R}_c^{[1]} $, which is differentiable with respect to a given parameter $ \theta $ (say), is defined by

    $ ΥR[1]cθ=R[1]cθθR[1]c.
    $
    (4.1)

    From direct calculation and without using the numerical values we can determine the signs of sensitivity indices with respect to some of the parameters. For the remaining sensitivity indices, we need to take help of the numerical examples. The normalized forward sensitivity indices of $ \mathcal{R}_c^{[1]} $ with respect to the parameters which are found to be clearly positive are given by,

    $ ΥR[1]cβ=1>0,ΥR[1]cp1=β(1σ)p1ηR[1]c>0,ΥR[1]cp2=βp2δR[1]c>0,
    $
    (4.2a)
    $ ΥR[1]cp3=βζ1σp3A1A2R[1]c>0,ΥR[1]cp4=βσζ3p4A1A3R[1]c+βσξ1ζ1p4A1A2A3R[1]c>0,
    $
    (4.2b)

    where $ A_1\, = \, \rho_1+\zeta_1+\zeta_2+\zeta_3 $, $ A_2\, = \, \xi_1+\xi_2 $ and $ A_3\, = \, \rho_2+\nu $.

    The normalized forward sensitivity indices of $ \mathcal{R}_c^{[1]} $ with respect to the parameters which are found to be clearly negative are given by,

    $ ΥR[1]cη=βp1(1σ)ηR[1]c<0,ΥR[1]cρ2=[p4σζ3A2+p4σξ1ζ1]A1A2A23βρ2R[1]c<0,
    $
    (4.3a)
    $ ΥR[1]cρ1=[σA2A3+p3ζ1σA3+p4σζ3A2+p4σξ1ζ1A21A2A3]βρ1R[1]c<0,
    $
    (4.3b)
    $ ΥR[1]cζ2=[σA2A3+p3ζ1σA3+p4σζ3A2+p4σξ1ζ1A21A2A3]βζ2R[1]c<0,
    $
    (4.3c)
    $ ΥR[1]cν=[p4σζ3A2+p4σξ1ζ1]A1A2A23βνR[1]c<0,ΥR[1]cξ2=[p3ζ1σA3+p4σξ1ζ1]A1A22A3βξ2R[1]c<0,
    $
    (4.3d)
    $ ΥR[1]cδ=βp2δR[1]c<0.
    $
    (4.3e)

    The signs of normalized forward sensitivity indices of $ \mathcal{R}_c^{[1]} $ with respect to rest of the parameters can not be determined from their explicit expressions and we need to take help of some numerical examples. Such normalized forward sensitivity indices are as follows,

    $ ΥR[1]cσ=[p1η+1A1+p3ζ1A1A2+p4ζ3A1A3+p4ξ1ζ1A1A2A3]βσR[1]c,
    $
    (4.4a)
    $ ΥR[1]cζ1=[σ(ρ2+ν)+p4σζ3A1A3+(ρ1+ζ2+ζ3)p3σA3+p4σξ1A21A2A3]βζ1R[1]c,
    $
    (4.4b)
    $ ΥR[1]cζ3=[p4σA1(ρ1+ζ1+ζ2)2A3σA2A3+p3ζ1σA3+p4σξ1ζ1A21A2A3]βζ3R[1]c,
    $
    (4.4c)
    $ ΥR[1]cξ1=[p3ζ1σA1A22+p4σζ1ξ2A1A22A3]βξ1R[1]c.
    $
    (4.4d)

    We use the sensitivity indices to understand parameters that have a high impact on $ \mathcal{R}_c^{[1]} $. The values of the sensitivity indices for different parameters depend on the choice of parameter values. As we have mentioned earlier, the values of the sensitivity indices can be positive or negative. The most positive (or negative) value of the sensitivity index for a parameter indicates that parameter is most sensitive to $ \mathcal{R}_c^{[1]} $ and the least positive (or negative) value of the sensitivity index for a parameter indicates that parameter is least sensitive to $ \mathcal{R}_c^{[1]} $.

    The sensitivity index may depend on several parameters of the system, but also can be constant, independent of any parameter. For example, $ \Upsilon_{\beta}^{\mathcal{R}_c^{[1]}} = 1 $ means that an increase (decrease) in $ \beta $ by a given percentage will result in increase (decrease) in $ \mathcal{R}_c^{[1]} $ by the same percentage. The estimation of a sensitive parameter should be carefully done, since a small perturbation in such parameter leads to relevant quantitative changes. On the other hand, the estimation of a parameter with a rather small value for the sensitivity index does not require as much attention to estimate, because a small perturbation in that parameter leads to small changes. From Table 2, we conclude that the most sensitive parameters to the basic reproduction number $ \mathcal{R}_c^{[1]} $ of the COVID-19 model (2.1) are $ \beta, p_1, p_2, \eta, \sigma, \delta $. In concrete, an increase of the value of $ \beta, p_1, p_2, \sigma $ will increase the basic reproduction number by $ 100\% $, $ 33.4\% $, $ 29.69\% $, $ 33.21\% $ respectively and an increase of the value of $ \eta, \delta $ will decrease $ \mathcal{R}_c^{[1]} $ by $ 33.4\% $ and $ 29.69\% $ respectively. Sensitivity indices with respect to the parameter values as presented in Table 2 can be visualized from Figure 4.

    Table 2.  Initial parameter values used as the initial guess for the model (2.1) and sensitivity indices of $ \mathcal{R}_c^{[1]} $ with respect to the parameters and values mentioned here.
    Parameter Values Sensitivity Index
    $ \beta $ varying 1
    $ p_1 $ 0.2 0.3340
    $ p_2 $ 0.2 0.2969
    $ p_3 $ 0.2 0.0158
    $ p_4 $ 0.2 0.0634
    $ \delta $ 0.75 –0.2969
    $ \sigma $ 0.1 0.3321
    $ \eta $ 0.6 –0.3340
    $ \rho_1 $ 0.1 –0.09
    $ \rho_2 $ 0.07 –0.0477
    $ \zeta_1 $ 0.07 0.0348
    $ \zeta_2 $ 0.1 –0.09
    $ \zeta_3 $ 0.14 0.0417
    $ \xi_1 $ 0.14 –0.0015
    $ \xi_2 $ 0.1 –0.0143
    $ \nu $ 0.05 –0.0341

     | Show Table
    DownLoad: CSV
    Figure 4.  Sensitivity indices of $ \mathcal{R}_c^{[1]} $ with respect to the parameters involved with the model (2.1) and their reference values as mentioned in Table 2.

    We have fitted the parameters $ \beta $, $ p_1 $, $ p_2 $, $ p_3 $, $ p_4 $, $ \mu $, $ \delta $, $ \sigma $, $ \eta $, $ \rho_1 $, $ \xi_2 $ for the range of the values given in Table 1 and took $ \zeta_1 $, $ \zeta_2 $, $ \zeta_3 $, $ \xi_1 $, $ \rho_2 $, $ \nu $ fixed as given in Table 1. We estimated those values for three different time intervals (1–30th day, 31–42nd day, 43–95th day). We have considered the initial values of the parameters as given in Table 2. We have chosen the time interval and end values of different compartments from the fittings over the previous time intervals. Here we have considered $ \frac{\beta S}{N} (I_s+p_1I_a+p_2E_2+p_3Q+p_4J) $ as the daily reported case and the sum of this part over the desired time interval is considered as cumulative number of infected cases.

    The optimization of parameters to describe the outbreak of COVID-19 in Germany was fitted by minimizing the Sum of Squared Errors (SSE), in such a way that the solutions obtained by the model approximate the reported cumulative number of infected cases. We applied three searches to minimize the SSE function: by using a gradient-based method first, followed by a step of minimization with a gradient-free method, again followed by a third step of gradient-based method. MATLAB based nonlinear least-square solver fmincon and patternsearch are used to fit simulated and observed daywise cumulative number of infected cases for three different time intervals. Detailed description of this method and its implementation can be found in [20,37,38,39].

    The model (2.1) is simulated with best fitted parameter values as mentioned above and the simulation result against the daily reported data and cumulative data are presented in Figure 5a. In this case the values of $ \beta $ are constants over three different range of days starting from the initial date of COVID-19 epidemic spread in Germany. For this figure some of the parameters are estimated as described above. Another simulation result is presented in Figure 5b where initially the value of $ \beta $ is constant for several days, and then monotone decreasing over a range of days and then remain constant for the rest of the period. The variation of $ \beta $ with respect to time is shown in Figure 6. Interestingly the data are fitted well in the case of time varying $ \beta $ where $ \beta(t) $ is continuous. For the simulation result presented in Figure 5b, the number of days for which $ \beta(t) $ remains constant and then starts decaying are adjusted in such a way that the outcome matches well with both the cumulative and daily data. Accordingly the slope of decaying $ \beta(t) $, the day up to which it decays and the lower value of $ \beta(t) $ are chosen. The numerical simulation and fitting with the data are carried out with the objective that the simulation result should be pretty close to the cumulative number of reported cases. We can claim that our attempt is successful as the cumulative number of reported cases for Germany on 15th May, 2020 obtained from the simulation is 180, 788 and the reported data (see [3]) shows it is equal to 182, 250. In this case the choice of $ \beta(t) $ is as shown in Figure 6a. Cumulative number of reported cases obtained from the simulation with the $ \beta(t) $ as shown in Figure 6b is equal to 180, 808. Both the simulated values are close to the reported data. Relative percentage error is less that $ 1\% $ and is precisely equal to $ 0.79\% $.

    Figure 5.  Blue curves indicate the model simulation and the red dotted curves indicate the reported data for cuculative infected population. Simulation results are obatined for two different forms of $ \beta(t) $, (a) with $ \beta(t) $ as shown in Figure 6a; (b) with $ \beta(t) $ as shown in Figure 6b.
    Figure 6.  The values of $ \beta $ changing with time $ t $ and used in (a) Figure 5a and (b) Figure 5b respectively.

    Simulations and fitting are done with the reference to cumulative number of reported cases. However, the obtained results are also in good agreement with the daily data. As there is no uniformity of the daily reported cases, may be due to irregular reporting, we have used 7 days moving agerage as daily data instead of daily raw data. Simulation results with two different types of $ \beta(t) $ and 7 days moving average for daily reported data are shown in Figure 7. The estimated and other parameter values for the simulation with $ \beta(t) $ constant over three different time intervals are presented in Table 3 along with the sensitivity incides.

    Figure 7.  Simulation results and daily reported cases (7 days moving average) for two different form of $ \beta(t) $. Blue curve and magenta curves are for $ \beta(t) $ as shown in Figure 6a and Figure 6b respectively.
    Table 3.  Best fitted values for the parameters of (2.1) for Germany.
    Parameter Best fit values Best fit values Best fit values
    for 1st 30 days for next 12 days upto 95th day
    (Sensitivity Index) (Sensitivity Index) (Sensitivity Index)
    $ \beta $ 3.98 (1) 1.77 (1) 1.05 (1)
    $ p_1 $ 0.177 (0.2383) 0.16 (0.2204) 0.34 (0.5099)
    $ p_2 $ 0.3 (0.4039) 0.3 (0.4133) 0.05 (0.0914)
    $ p_3 $ 0.05 (0.0048) 0.05 (0.0049) 0.05 (0.0053)
    $ p_4 $ 0.05 (0.0192) 0.05 (0.0196) 0.05 (0.0213)
    $ \delta $ 1 (-0.4039) 1 (-0.4133) 0.82 (-0.0914)
    $ \sigma $ 0.1 (0.3314) 0.1 (0.3418) 0.1 (0.342)
    $ \eta $ 0.9 (-0.2383) 0.9 (-0.2204) 0.9 (-0.5099)
    $ \rho_1 $ 0.1 (-0.0873) 0.1 (-0.0893) 0.1 (-0.0972)
    $ \rho_2 $ 0.07 (-0.0144) 0.07 (-0.0148) 0.07 (-0.0161)
    $ \zeta_1 $ 0.07 (-0.0067) 0.07 (-0.0069) 0.07 (-0.0075)
    $ \zeta_2 $ 0.1 (-0.0873) 0.1 (-0.0893) 0.1 (-0.0972)
    $ \zeta_3 $ 0.14 (-0.0715) 0.14 (-0.0732) 0.14 (-0.0796)
    $ \xi_1 $ 0.14 (-0.00047) 0.14 (-0.00048) 0.14 (-0.00052)
    $ \xi_2 $ 0.1 (-0.0043) 0.1 (-0.0044) 0.1 (-0.0048)
    $ \nu $ 0.05 (-0.0103) 0.05 (-0.0105) 0.05 (-0.0115)
    $ \mu $ 0.28 ($ – $) 0.28 ($ – $) 0.28 ($ – $)

     | Show Table
    DownLoad: CSV

    Consideration of changing $ \beta $ over different range of durations is an important observation of our present work. It is important to mention that the number of intervals over which we have to take different values of $ \beta $ is not always limited to three as in the case of Germany. The number of intervals over which we need to choose different values of $ \beta $ in order to match the simulation results with the data from different countries varies significantly. Of course, in all such simuations the values of $ \beta $ are decreasing with respect to the number of days. The simulations results for three more countries, namely Italy, UK and Spain, are provided in the appendix along with the result for Germany again where the 95% confidence intervals are shown. The parameter values used, the range of days over which $ \beta $ remains constant and estimated parameter values are also provided in the appendix.

    In order to understand the usefulness of the model (3.1), we now present some numerical simulation results. In Figure 5 we have presented the simulation results for the model (2.1) up to 19th of May. For the fitting with daily data, we have obtained three different values of $ \beta $ as $ \beta_1 = 3.98 $, $ \beta_2 = 1.77 $ and $ \beta_3 = 1.05 $. The partial lockdown was started at Germany on 13th March, 2020 and then went into complete lock lockdown step by step. The process of unlocking at the essential sectors were started from 15th of May, 2020 and by that time the spreading speed of COVID-19 was much reduced. There are several restrictions like using mask, maitaining social distances and couple of other restrictions are in place in order to prevent the further spread of the disease. As of now the disease is not completely eradicated rather a minor number of cases are getting reported on a regular basis but the situation is seem to be under control.

    We are interested to see the situation if all the citizens do not follow the suggested restrictions then what can happen afterward. For this purpose we now perform an interesting numerical simulations. We have simulation results for the model (2.1) as described at the previous subsection up to 19th of May. Now we start simulating the model (3.1) from the day immediately after 19th May and continue up to the end of November 2020. We assume that a fraction of population are not following the guideline and other fraction is following the safety and preventive norms appropriately. Let us define the ''coefficient of social interactions'' as $ S_1/N $ and is denoted by $ K $. If we assume that the 10% of the population is not following the norm then $ S_1/N\equiv K = 0.1 $ and hence $ S_2/N = 0.9 = 1-K $. We assume that $ \beta_{11} = \beta_1 $, $ \beta_{22} = \beta_3 $ and $ \beta_{12} = \beta_{21} = (\beta_1+\beta_3)/2 $ where $ \beta_j $ ($ j = 1, 2, 3 $) are the values determined by fitting the data with the first model. Initial densities of $ E_{11} $ and $ E_{21} $ can be distributed with the same proportion to $ K $ and $ 1-K $ of the value of $ E_1 $ on 19th May. Same procedure is adopted for other components except $ Q $, $ J $ and $ R $. For simplicity we also assume that the other parameters involved with the two group model are equal to the values of the corresponding parameter involved with the model (2.1) and is equal to the numerical values as mentioned at the last column of Table 3. For clearer understanding we can mention here some of the parameter values: $ p_{j1} = p_1 = 0.34 $ ($ j = 1, 2, 3, 4 $), $ \sigma_1 = \sigma_2 = \sigma = 0.1 $ and so on.

    With above choice of initial values and parameter values now we simulate the model (3.1) up to the end of November, 2020. Two different simulations are performed and the simulation results are presented in Figure 8. For first simulation we have considered $ K = 0.1 $ fixed up to the end of November 2020 (see Figure 8a). Second simulation is performed for $ K = 0.1 $ upto the end of August and then $ K = 0.15 $ during September to November 2020. In the figure we have ploted the consolidated compartments $ E_1 $, $ E_2 $, $ I_a $ and $ I_s $ in order to avoid any confusion where we have obtained the values of these compartments by adding the values of the respective compartments in two group. To be specific, $ E_1 = E_{11}+E_{12} $ and similary for other compartments. A relatively small increase of $ K $ lead to an essential acceleration in the disease progression.

    Figure 8.  Time evolution of $ E_1 $, $ E_2 $, $ I_a $ and $ I_s $ obtained from the numerical simulation of the two models (2.1) and (3.1) from 15th February to 30th November 2020 as described in the text. Two different values of $ K $ are used for the duration 1st September to 30th November, (a) $ K = 0.1 $ and (b) $ K = 0.15 $.

    With the parameter setup mentioned above one can calculate the controlled reproduction number $ \mathcal{R}_c^{[2]} $ using the detailed formula given in Sub-section 3.1. Without any loss of generality we can make a crude assumption that $ \frac{N_1}{N} = K $ in order to find a value of $ \mathcal{R}_c^{[2]} $. Clearly the measure for $ \frac{N_2}{N} $ will be $ 1-K $. With $ K = 0.1 $, we can see slow growth in exposed and infected compartments as shown in Figure 8a as we find $ \mathcal{R}_c^{[2]} = 1.089 $. Now if we change the value of $ K $ to $ K = 0.15 $ the revised measure of $ \mathcal{R}_c^{[2]} $ becomes $ \mathcal{R}_c^{[2]} = 1.219 $. These results ensure the usefulness of our model along with the mathematical details and supportive numerical simulations.

    Most of the important features and several issues related to COVID-19 remain unclear and immense scientific efforts are required to understand various important issues. As it is reported at many sources that some of the recovered individuals can become infected after a certain period of time as the recovery is seems to be temporary [40]. In this section we want to revisit the model (2.1) with the modification that a fraction of recovered population can return back to the susceptible class. We are mainly interested to calculate the final size of the infected compartment due to fact that the recovered individuals join the susceptible class after a certain number of days. In order to find a rough estimate of the size of the infected compartment and to obtain their estimate explicitly we can make a crude assumption. The assumption is that the disease related death rate is negligible. With these assumptions the model (2.1) with relapse of the disease can be written as follows

    $ dSdt=βSN(Is+p1Ia+p2E2+p3Q+p4J)+ϵR,
    $
    (5.1a)
    $ dE1dt=βSN(Is+p1Ia+p2E2+p3Q+p4J)μE1,
    $
    (5.1b)
    $ dE2dt=μE1δE2,
    $
    (5.1c)
    $ dIadt=(1σ)δE2ηIa,
    $
    (5.1d)
    $ dIsdt=σδE2(ζ1+ζ2+ζ3)Is,
    $
    (5.1e)
    $ dQdt=ζ1Is(ξ1+ξ2)Q,
    $
    (5.1f)
    $ dJdt=ζ3Is+ξ1QνJ,
    $
    (5.1g)
    $ dRdt=ηIa+ζ2Is+ξ2Q+νJϵR.
    $
    (5.1h)

    This model admits an endemic equilibrium point apart from the disease free equilibrium point. Let us denote the components of endemic equilibrium point as $ (\bar{S}, \bar{E}_1, \bar{E}_2, \bar{I}_a, \bar{I}_s, \bar{Q}, \bar{J}, \bar{R}) $, then equating the right hand sides of (5.1c)–(5.1g) to zero, we find

    $ ˉE1=ζ1+ζ2+ζ3μσˉIs,ˉE2=ζ1+ζ2+ζ3σδˉIs,ˉIa=(1σ)(ζ1+ζ2+ζ3)σηˉIs,ˉQ=ζ1ξ1+ξ2ˉIs,ˉJ=(ξ1ζ1ν(ξ1+ξ2)+ζ3ν)ˉIs.
    $

    Now equating the right hand sides of (5.1a) and (5.1b) to zero and then adding, we can find

    $ \bar{R}\, = \, \frac{\zeta_1+\zeta_2+\zeta_3}{\epsilon\sigma}\bar{I}_s. $

    Now we consider the following equation obtained from (5.1b),

    $ \frac{\beta \bar{S}}{N}(\bar{I}_s+p_1\bar{I}_a+p_2\bar{E}_2+p_3\bar{Q}+p_4\bar{J})\, = \, \mu \bar{E}_1. $

    Using the expressions for $ \bar{E}_1 $, $ \bar{E}_2 $, $ \bar{I}_a $, $ \bar{Q} $, $ \bar{J} $ in terms of $ \bar{I}_s $, we can write

    $ \frac{\beta \bar{S}}{N}\left(1+\frac{\zeta_1+\zeta_2+\zeta_3}{\sigma}\left(\frac{p_1}{\delta}+\frac{p_2(1-\sigma)}{\eta}\right)+\frac{p_3\zeta_1}{\xi_1+\xi_2}+p_4\left(\frac{\xi_1\zeta_1}{\nu(\xi_1+\xi_2)}+\frac{\zeta_3}{\nu}\right)\right)\, = \, \frac{\zeta_1+\zeta_2+\zeta_3}{\sigma}, $

    and then using $ \bar{S}\, = \, N-\bar{E}_1-\bar{E}_2-\bar{I}_a-\bar{I}_s-\bar{Q}-\bar{J}-\bar{R} $ and the relevant expressions we can find

    $ ˉIs=N(1B1)B2,
    $
    (5.2)

    where

    $ B_1\, = \, \frac{\zeta_1+\zeta_2+\zeta_3}{\sigma\beta\left(1+\frac{\zeta_1+\zeta_2+\zeta_3}{\sigma}\left(\frac{p_1}{\delta}+\frac{p_2(1-\sigma)}{\eta}\right)+\frac{p_3\zeta_1}{\xi_1+\xi_2}+p_4\left(\frac{\xi_1\zeta_1}{\nu(\xi_1+\xi_2)}+\frac{\zeta_3}{\nu}\right)\right)}, $
    $ B_2\, = \, 1+\frac{\zeta_1+\zeta_2+\zeta_3}{\sigma}\left(\frac{1}{\mu}+\frac{1}{\delta}+\frac{1-\sigma}{\eta}+\frac{1}{\epsilon}\right)+ \frac{\zeta_1}{\xi_1+\xi_2}+\left(\frac{\xi_1\zeta_1}{\nu(\xi_1+\xi_2)}+\frac{\zeta_3}{\nu}\right). $

    In order to come up with a closed form of estimate for the endemic steady-state in case of relapse of the disease, we have assumed that the number of COVID-19 related death is negligible. In reality this is not true however it help us to have a rough estimate for the endemic steady-state dependning upon the value of $ \epsilon $. The parameter $ \epsilon $ is related to the relapse rate as $ \frac{1}{\epsilon} $ is the average number of days after which a recovered individual can have fresh infection. It is diffcult to derive explicit condition for which $ B_1 $ is less than one in order to have a feasible values for the components of endemic equilibrium point in case of replase. In order to have a feasible values of $ \bar{I}_s $ and other components we should have $ B_1 < 1 $. Interestingly, with the parameter values mentioned at the last column of Table 3, we can calculate $ B_1 = 1.12 $ where $ \beta = 1.07 $ and note that $ \mathcal{R}_c^{[1]}\, = \, 0.7002 $. In order to have an admissible value of $ B_1 $, if we consider $ \beta = 1.2 $ and with other parameter values are same as in the third column of Table 3 we find $ B_1 = 0.98 $ although $ \mathcal{R}_c^{[1]} $ remains less than one. Finally assuming $ \epsilon = 0.01 $, that is recovered individuals can join the susceptible class after 100 days on an average, we find $ \frac{1-B_1}{B_2}\approx6\times10^{-5} $. So a rough idea about the estimated number of infected individuals at the endemic state will be $ 6\times10^{-5}\times N $ where $ N $ is the total population of the country. The measure $ \frac{1-B_1}{B_2} $ decreases with the decrease in $ \epsilon $ as we can calculate $ \frac{1-B_1}{B_2}\approx0.000031, \, 0.000021 $ for $ \epsilon = 0.005, \, 0.0033 $ respectively.

    A wide range of mathematical approaches are adopted to develop viable mathematical model to understand the propagation of disease spread for COVID-19. The proposed mathematical models are not only diffierent in the context of basic assumptions behind the model formulation, rather incomplete or unclear understanding of disease spread for COVID-19 is another burden. In this paper we have proposed and analyzed an ordinary differential equation model to study the COVID-19 disease propagation which consists of fundamentally six compartments. The basic compartments are susceptible, exposed, infected, quarantined, hospitalised and recovered. It is evident that all the exposed individuals can not spread the disease and hence the exposed compartment is divided into two sub-compartments $ E_1 $ and $ E_2 $ where the individuals belonging to the second compartment can infect the healthy individuals. Once the incubation period is over, exposed individuals are becoming actively infected which means they can infect other individuals. In case of COVID-19 disease, every infected individuals are not developing appropriate symptoms and asymptomatic individuals can recovered from the disease without any serious medical intervention. The infected compartment is divided into two compartments, namely, asymptomatic infected and symptomatic infected.

    There is a significant variation in the collection and reporting of infected data and no uniformity is maintained so far due to the rapid spread of the disease. From huge dataset, it is quite difficult to understand when an individual is identified as a COVID-patient but at which category they belong to (whether an individual belongs to $ E_1 $, $ E_2 $, $ I_a $ or $ I_s $ compartment). Without any loss of generality we can assume that the individuals belonging to $ I_a $ and $ I_s $ are tested to be positive. Once an individual is tested to be positive, he/she needs to follow the appropriate guideline of the country and hence they will be under isolation or quarantine assuming that they do not need any medical intervention through hospitalization. Hence we have assumed that the individuals from $ I_a $ compartment directly move to the recovered compartment and hospitalization is required for certain fraction of individuals belonging to sysmptomatic infected and quarantined compartments. COVID-19 related death is assumed for the $ I_s $ and $ J $ compartments only. As the quarantined individuals are monitored on a regular basis and the healthcare service is supposed to be effective, hence every needy individuals can be moved to the hospital as per requirement. Based upon these assumptions we have considered two models here, epidemic model (2.1) and two group epidemic model (3.1). Interesting and significant contribution of our work is the consideration of time dependent rate of infection over various periods of time. This variation is adopted into the model in order to capture the effect of lockdown, social distancing etc. which play a crucial role to reduce the disease spread. The date of implementation of lockdown and the extent of lockdown varies from one country to another. Total lockdown is rarely implemented, rather most of the European countries went to step-by-step lockdown and sometimes they imposed complete lockdown at some states and/or provinces instead of total lockdown accross the country.

    Parameter identification has a crucial importance in the epidemiological models. Some of the parameters, such as average durations of the incubation period and of hospitalization, can be evaluated from the clinical data. Some other parameters or their combinations are estimated by fitting the epidemiological data, in particular, the reported number of infected cases. However, even the combination of available methods of parameter identification does not usually allow a unique determination of all parameters. Different combinations of parameters can give a similar fitting accuracy. This means that the values of individual parameters cannot be uniquely determined. In spite of this uncertainty, the results of such modelling can have some predictive value because relative variation of parameters can be more important that their absolute values. As such, according to modelling, a slight increase of the coefficient of social interaction can lead to the second wave of epidemic, what is observed in Israel, Spain, France in July-September 2020. Therefore, we can evaluate necessary measures to stop this progression imposing stricter social distancing.

    In this present work we have considered different durations of the period of time when the rate of infection varies in order to match the simulation results with the cumulative number of reported infected individuals for four countries. The magnitudes of $ \beta(t) $ over various intervals are obtained through fitting the simulated result with data but the choice of different periods remain in our hand. One can argue that the obtained results might change with a variant assumption but at the same time we can claim the appropriate nature of varying infectivity is not much clear yet. In order to show the effectiveness of our analysis, the fitting is done for the data from four different countries. It is important to mention here that the fitting with daily data seems to be not in good agreement (we can see significant variation around the fitted curve) but at the same time we need to keep in mind the irregularity of the reporting protocol. It is a matter of fact that several contries have changed their reporting mechanism time to time alongwith the change in the process of testing. A natural question may arise that we are considering constant $ \beta(t) $ over different time intervals, so what will be the outcome if we match the simulation result with the daily data or 7 days moving average? The answer is that either we need to change $ \beta(t) $ in daily basis which is not a good idea for fitting the simulation results of ordinary differential equation models with the data or we can observe a significant disagreement with the cumulative number of reported cases. For numerical simulation of the model (2.1) we have obtained three different values of $ \beta $ and we can calculate the controlled basic reproduction numbers accordingly. For the set of parameter values as mentioned in the three columns of Table 3, we can calculate the controlled reproduction numbers as $ \mathcal{R}_c^{[1]}\, = \, 2.9565, \, 1.2847, \, 0.7002 $. In Section 2 we have calculated the basic reproduction number $ \mathcal{R}_0 $, for model (2.1), apart from the controlled reproduction number $ \mathcal{R}_c^{[1]} $. If we calculate the basic reproduction number $ \mathcal{R}_0^{[1]} $ for model (2.1) with the parameter values given in the first column of Table 3, we find $ \mathcal{R}_0^{[1]} = 3.888 $ which is quite higher than $ \mathcal{R}_c^{[1]} $. It clearly indicates that the disease can propagate much faster in the absence of the control measures.

    Epidemiological data on COVID-19 epidemic provide the number of registered infection cases on the bases of PCR tests, the number of hospitalized, recovered and dead (see, e.g., [3]). The number of positive tests depends on the total number of effectuated tests. However, if the organization of testing remains the same during some period of time, we can reasonably assume that the number of registered cases represents the total number of cases with some proportionality coefficient. In particular, if infected individuals apply to the medical care in the case of severe symptoms, subsequently tested and identified as positive cases, we can take into account that severe cases represent some given proportion of the total number of cases. Furthermore, since at the beginning of epidemic the number of susceptible individuals remains close to the total population, then the model is approximately linear, and the size of all sub-classes can be obtained by the same proportionality coefficient. On the other hand, some countries practiced a wide testing allowing a reliable estimate of the total number of infected cases. Overall, in spite of certain difficulties in the estimation of the number of infected individuals, we can reasonably assume that available epidemiological data faithfully reflects the real situation.

    The proposed two group epidemic model can capture the situation when one group of people are following the social distancing norm, using face mask appropriately and other group is not obeying the safety norms. We must admit that the data and relevant information for the parameter values involved with the model (3.1) are not available yet. But the numerical simulation shows that if 10% or more of the population start violating the safety norms then there is a resonable chance that the disease can relapse. It is difficult to predict the size of the next epidemic but our model is capable to capture the realistic scenario. The number of daily reported cases started increasing at some countries like Iran, Spain etc. (see the data avialbale at [3]) compared to the number of reported infections on the days close the end of complete lockdown.

    The coefficient of social interaction $ K $ introduced in Section 4.3 characterizes the intensity of the interaction between susceptible and infectious individuals, and it determines the rate of disease progression. The value $ K = 0 $ corresponds to complete lockdown, and $ K = 1 $ to the absence of lockdown. Partial measures of social distancing after the end of lockdown in a number of European countries restrain its value to $ K \approx 0.1 $ characterized by a slow growth of the number of infected individuals. Even a slight increase of this coefficient up to $ K = 0.15 $, which can be expected in September due to the end of vacation season and the beginning of academic year, can lead to an important burst of epidemic.

    Currently available data for the unlocking period/post lockdown period indicates a significant increase in daily reported cases in Italy, full scale second wave of epidemic in Spain. There is not significant increase in number of case in Germany for which we have given much emphasis. Based upon the recently available data for Spain, we have fitted our 2nd model with the daily reported cases for Spain where second wave in epidemic has been noticed and got the best fitted value of $ K $ as $ 0.3 $ for which our model simulation has a good agreement with the real data for daily reported cases. The fitting with data in presented in Figure 9, all the parameter values are mentioned at the appendix. The choices of different parameters involved with the model (3.1) are the same as discussed in the previous section. The choices of $ \beta_{ij} $ are $ \beta_{11} = \beta_1 $, $ \beta_{22} = \beta_4 $ and $ \beta_{12} = \beta_{21} = (\beta_1+\beta_4)/2 $.

    Figure 9.  Simulation result for the model (3.1) with parameter values as mentioned in the text and appendix and validation with the data for Spain.

    We have calculated the final size of the epidemic for both the models considered in this manuscript and obtained a rough estimate for the endemic steady-state analytically. The final size of the epidemic are calculated assuming $ \beta $ is constant however the numerical simulations are carried out for non-constant $ \beta $ and their variation with time is already explained clearly. Here we justify the analytical findings with supportive numerical results and argue for the effectivity of lockdown and imposition of several social restrictions. We mentioned above that the controlled reproduction number for Germany is $ \mathcal{R}_c^{[1]}\, = \, 2.9565 $ with $ \beta = \beta_1 = 3.98 $. With this value of $ \mathcal{R}_c^{[1]} $, solving the equation (2.19) we find $ x = 0.06303 $. With the current population size of Germany which is approximately equal to 82.9 million gives us final size as $ S_f = 5, 225, 187 $. The $ 95\% $ confidence interval for the final size is given by $ [4.7194\times10^6, \, 5.1958\times10^6] $. This result clearly indicates that a huge number of people could be infected if no such restriction was imposed. Similar calculations can be done for other compartments as well for two group model also. But we skip them here for the sake of brevity and will address this issue in our future endevour with appropriate estimates for the values of other parameters involved with the second model.

    Control of the progression of COVID-19 epidemic goes beyond pure epidemiological questions. There are several societal aspects that can be important including the strategy chosen to handle the epidemic, and how people react on the measures of social distancing. In particular, at the first stage of epidemic, different measures were adopted according to the decisions of public authorities. Stricter measures of social distancing were introduced in China, while more liberal in Europe, especially, in Sweden. Tracing of infection chains with a large number of tests was applied in South Korea and in Germany. The results of these different strategies were also different, and they should be analyzed in more detail. The efficiency of lockdown introduced in many countries and post-lockdown evolution of the epidemiological situation depend on many factors. In particular, the application of the measure of social distancing can be influenced by some national traditional and historical features such as family meetings, festivities, religious meetings and holidays, and so on. Epidemic progression can also influence public opinion and mass media, which in their turn influence the intensity of social interactions [26,41].

    The second author's (VV) work is supported by the Ministry of Science and Higher Education of the Russian Federation: agreement no. 075-03-2020-223/3 (FSSF-2020-0018).

    The authors declare no conflicts of interest in this paper.

    Proof of Th. 1: By re-writing the system (2.1) we have

    $ \frac{dX}{dt} = B(X), \, \, X(0) = X_0\geq0, $

    where

    $ X\, = \, (S, E_1, E_2, I_a, I_s, Q, J, R)^T, $
    $ B(X)\, = \, (B_j(X))^T, \, \, j = 1, 2, \cdots, 8, $

    with

    $ B_1(X)\, = \frac{\beta S}{N}(I_s+p_1I_a+p_2E_2+p_3Q+p_4J), $

    and so on. We note that

    $ dSdt|S=0=0,dE1dt|E1=0=βSN(Is+p1Ia+p2E2+p3Q+p4J)0,dE2dt|E2=0=μE10,dIadt|Ia=0=(1σ)δE20,dIsdt|Is=0=σδE20,dQdt|Q=0=ζ1Is0,dRdt|R=0=ηIa+ζ2Is+ξ2Q+νJ0.
    $

    The inequalities mentioned above hold for any point belonging to the interior of $ \mathbb{R}^{8}_{+} $ or on the boundary hyper-planes. Solutions starting from a non-negative initial condition and non-negativity of the time derivaties imply that the system (2.1) is invariant in $ \mathbb{R}^{8}_{+} $.

    The matrices $ \mathcal{F}_1 $ and $ \mathcal{V}_1 $ are defined by

    $ F1=[βSN(Is+p1Ia+p2E2)00000],V1=[μE1δE2μE1ηIa(1σ)δE2(ρ1+ζ2)IsσδE2βSN(Is+p1Ia+p2E2)ηIaζ2Is].
    $

    The matrices $ F_1 $ and $ V_1 $ are given by

    $ F1=[0βp2βp1β000000000000],V1=[μ000μδ000(1σ)δη00σδ0ρ1+ζ2].
    $
    (6.2)

    Now, we can calculate,

    $ F1V11=[β(p2δ+(1σ)p1η+σρ1+ζ2)β(p2δ+(1σ)p1η+σρ1+ζ2)βp1ηβρ1+ζ2000000000000].
    $

    $ \mathcal{F}_2 $ and $ \mathcal{V}_2 $ are given by

    $ F2=[βSN(Is+p1Ia+p2E2+p3Q+p4J)0000000],V2=[μE1δE2μE1ηIa(1σ)δE2(ρ1+ζ1+ζ2+ζ3)IsσδE2(ξ1+ξ2)Qζ1Is(ρ2+ν)Jζ3Isξ1QβSN(Is+p1Ia+p2E2+p3Q+p4J)(ηIa+ζ2Is+ξ2Q+νJ)].
    $

    These two matrices $ F_2 $ and $ V_2 $ are given by

    $ F2=[0βp2βp1ββp3βp4000000000000000000000000000000],
    $
    $ V2=[μ00000μδ100000(1σ)δ1η0000σδ10(ρ1+ζ1+ζ2+ζ3)00000ζ1(ξ1+ξ2)0000ζ3ξ1(ρ2+ν)].
    $

    Explicit expressions for the matrices $ F_3 $ and $ V_3 $ are given below,

    $ F3=[00β11p12N1Nβ12p22N1Nβ11p11N1Nβ11p21N1Nβ11N1Nβ12N1NβQN1NβJN1N00β21p32N2Nβ22p42N2Nβ21p31N2Nβ22p41N2Nβ21N2Nβ22N2NβQN2NβJN2N00000000000000000000000000000000000000000000000000000000000000000000000000000000],
    $
    $ V3=[μ10000000000μ200000000μ10δ100000000μ20δ200000000(1σ1)δ10η100000000(1σ2)δ20η2000000σ1δ1000α1000000σ2δ2000α200000000ζ11ζ21ξ1+ξ20000000ζ12ζ22ξ1ρ2+ν].
    $

    Here we present the numerical simulation results and fitting with the data alongwith the 95% confidence intervals for Germany, Italy, Spain and UK. The data used for these fiiting are available at [3]. The model (2.1) is used to perform the simulations and fitting with data. Parameterization are also the same as we have explained in Table 1. Details of the parameter values and their estimates for Germany are provided in Table 3. Parameter values and and their estimates for rest of the countries are provided below. It is worthy to mention here that the values of $ \beta(t) $ are estimated over requisite number of intervals in order to have a good fit with the cumulative reported number of infected individuals. As a result the number of intervals over which $ \beta(t) $ is changing its constant magnitude varies from one country to another. In case of Germany, the number of intervals over which $ \beta(t) $ takes different constant values are three whereas the number of intervals for $ \beta(t) $ is five when we considered the data for Italy. Also the number days over which the simulations are carried out is not unique as the date implementation of lockdown and its partial withdrawal varies from one country to another. For all the countries, we have started the simulation from the date 15th of February, 2020 and continued approximately up to the end of strict lockdown restrictions.

    Figure 10.  Simulation results and daily reported cases (7 days moving average) and 95% confidence interval for the data of Germany. (a) Cumulative data and simulation results, (b) daily data (7days moving average) and simulation results.
    Table 4.  Best fitted parameter values for Italy.
    Parameter for 1st 26 days for next 6 days for next 7 days for next 8 days upto 90th day
    $ \beta $ 4 2.89 2 1.3 1
    $ p_1 $ 0.34 0.05 0.05 0.05 0.34
    $ p_2 $ 0.34 0.34 0.34 0.34 0.21
    $ p_3 $ 0.05 0.05 0.05 0.05 0.05
    $ p_4 $ 0.05 0.05 0.05 0.05 0.05
    $ \delta $ 1 1 1 1 0.96
    $ \sigma $ 0.1128 0.1 0.1 0.1 0.1
    $ \eta $ 0.9 0.9 0.9 0.9 0.9
    $ \rho_1 $ 0.1 0.1 0.1 0.1 0.1
    $ \rho_2 $ 0.07 0.07 0.07 0.07 0.07
    $ \zeta_1 $ 0.07 0.07 0.07 0.07 0.07
    $ \zeta_2 $ 0.1 0.1 0.1 0.1 0.1
    $ \zeta_3 $ 0.14 0.14 0.14 0.14 0.14
    $ \xi_1 $ 0.14 0.14 0.14 0.14 0.14
    $ \xi_2 $ 0.1 0.1 0.1 0.1 0.1
    $ \nu $ 0.05 0.05 0.05 0.05 0.05
    $ \mu $ 0.28 0.28 0.28 0.28 0.28

     | Show Table
    DownLoad: CSV
    Figure 11.  Simulation results and daily reported cases (7 days moving average) and 95% confidence interval for the data of Italy. (a) Cumulative data and simulation results, (b) daily data (7days moving average) and simulation results.
    Table 5.  Best fitted parameter values for Spain.
    Parameter for 1st 26 days for next 6 days for next 7 days for next 8 days upto 90th day
    $ \beta $ 3.7 2.202 1.67 1.126
    $ p_1 $ 0.1928 0.297 0.34 0.05
    $ p_2 $ 0.34 0.34 0.34 0.34
    $ p_3 $ 0.05 0.05 0.05 0.34
    $ p_4 $ 0.05 0.05 0.05 0.05
    $ \delta $ 1 1 1 1
    $ \sigma $ 0.1 0.1 0.1 0.1
    $ \eta $ 0.9 0.9 0.9 0.9
    $ \rho_1 $ 0.1 0.1 0.1 0.0551
    $ \rho_2 $ 0.07 0.07 0.07 0.07
    $ \zeta_1 $ 0.07 0.07 0.07 0.07
    $ \zeta_2 $ 0.1 0.1 0.1 0.1
    $ \zeta_3 $ 0.14 0.14 0.14 0.14
    $ \xi_1 $ 0.14 0.14 0.14 0.14
    $ \xi_2 $ 0.1 0.1 0.1 0.1
    $ \nu $ 0.05 0.05 0.05 0.05
    $ \mu $ 0.28 0.28 0.28 0.28

     | Show Table
    DownLoad: CSV
    Figure 12.  Simulation results and daily reported cases (7 days moving average) and 95% confidence interval for the data of Spain. (a) Cumulative data and simulation results, (b) daily data (7days moving average) and simulation results.
    Table 6.  Best fitted parameter values for UK.
    Parameter for 1st 26 days for next 6 days for next 7 days for next 8 days upto 90th day
    $ \beta $ 2.03 4 2.89 1.15 1.01
    $ p_1 $ 0.05 0.1145 0.05 0.34 0.34
    $ p_2 $ 0.05 0.34 0.34 0.34 0.24
    $ p_3 $ 0.34 0.34 0.05 0.05 0.05
    $ p_4 $ 0.34 0.34 0.05 0.05 0.05
    $ \delta $ 0.5 1 1 1 1
    $ \sigma $ 0.18 0.1 0.1 0.1 0.1
    $ \eta $ 0.9 0.9 0.9 0.9 0.9
    $ \rho_1 $ 0.05 0.1 0.1 0.1 0.1
    $ \rho_2 $ 0.07 0.07 0.07 0.07 0.07
    $ \zeta_1 $ 0.07 0.07 0.07 0.07 0.07
    $ \zeta_2 $ 0.1 0.1 0.1 0.1 0.1
    $ \zeta_3 $ 0.14 0.14 0.14 0.14 0.14
    $ \xi_1 $ 0.14 0.14 0.14 0.14 0.14
    $ \xi_2 $ 0.05 0.05 0.1 0.1 0.1
    $ \nu $ 0.05 0.05 0.05 0.05 0.05
    $ \mu $ 0.28 0.28 0.28 0.28 0.28

     | Show Table
    DownLoad: CSV
    Figure 13.  Simulation results and daily reported cases (7 days moving average) and 95% confidence interval for the data of UK. (a) Cumulative data and simulation results, (b) daily data (7 days moving average) and simulation results.
    [1] Happé F (2015) Autism as a neurodevelopmental disorder of mind-reading. Abstr Book 3: 197–209.
    [2] Dover CJ, Le Couteur AL (2007) How to diagnose Autism. Arch Dis Child 92: 540–545. doi: 10.1136/adc.2005.086280
    [3] Jukić V, Arbanas G (2013) Diagnostic and Statistical Manual of Mental Disorders; Fifth Edition (DSM-5).Int J 57: 15461548.
    [4] Fombonne E (2009) Epidemiology of pervasive developmental disorders. Pediatr Res 65: 591–598. doi: 10.1203/PDR.0b013e31819e7203
    [5] Fombonne E, Quirke S, Hagen A (2009) Prevalence and interpretation of recent trends in rates of pervasive developmental disorders. McGill J Med 12: 73.
    [6] Weintraub K (2011) Autism counts. Nature 479: 22–24. doi: 10.1038/479022a
    [7] Nazeer A, Ghaziuddin M (2012) Autism spectrum disorders: Clinical features and diagnosis. Pediatr Clin North Am 59: 19–25. doi: 10.1016/j.pcl.2011.10.007
    [8] Zablotsky B, Black LI, Maenner MJ, et al. (2015) Estimated prevalence of autism and other developmental disabilities following questionnaire changes in the 2014 national health interview survey. Natl Health Stat Rep 2015: 1–20.
    [9] Hansen SN, Schendel DE, Parner ET (2015) Explaining the increase in the prevalence of autism spectrum disorders the proportion attributable to changes in reporting practices. JAMA Pediatr 169: 56–62. doi: 10.1001/jamapediatrics.2014.1893
    [10] Mostafa GA, ALayadhi LY (2012) Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: Relation to autoimmunity. J Neuroinflammation 9: 1–7.
    [11] Duan XY, Jia FY, Jiang HY (2013) Relationship between vitamin D and autism spectrum disorder. Chin J Contemp Pediatr 15: 698–702.
    [12] Newschaffer CJ, Croen LA, Daniels J, et al. (2007) The epidemiology of autism spectrum disorders. Annu Rev Public Health 28: 235–258. doi: 10.1146/annurev.publhealth.28.021406.144007
    [13] Christison GW, Ivany K (2006) Elimination diets in autism spectrum disorders: Any wheat amidst the chaff? J Dev Behav Pediatr 27: S162–S171. doi: 10.1097/00004703-200604002-00015
    [14] Meyer U, Feldon J, Dammann O (2011) Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 69: 26R–33R.
    [15] Wagner CL, Taylor SN, Dawodu A, et al. (2012) Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus. Nutrients 4: 208–230.
    [16] Abdulbari B, Oaa AHA, Saleh NM (2013) Association between vitamin D insufficiency and adverse pregnancy outcome: Global comparisons. Int J Womens Health 5: 523.
    [17] Georgieff MK (2007) Nutrition and the developing brain: Nutrient priorities and measurement. Am J Clin Nutr85: 614S620S.
    [18] Al-Farsi YM, Waly MI, Deth RC, et al. (2013) Impact ofnutrition on serum levels of docosahexaenoic acid among Omani children with autism. Nutrition 29: 11421146.
    [19] Bell JG, Mackinlay EE, Dick JR, et al. (2004) Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukotrienes Essent Fatty Acids 71: 201204.
    [20] Amminger GP, Berger GE, Schafer MR, et al. (2007) Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled pilot study. Biol Psychol 61: 551553.
    [21] Meguid NA, Atta HM, Gouda AS, et al. (2008) Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem 41: 10441048.
    [22] Meiri G, Bichovsky Y, Belmaker RH (2009) Omega 3 fatty acid treatment in autism. J Child Adolesc Psychopharmacol 19: 449451.
    [23] El-Ansary AK, Ben BAG, Al-Ayahdi LY (2011) Impaired plasma phospholipids and relative amounts of essential polyunsaturated fatty acids in autistic patients from Saudi Arabia. Lipids Health Dis 10: 63. doi: 10.1186/1476-511X-10-63
    [24] Yui K, Koshiba M, Nakamura S, et al. (2012) Effects of large doses of arachi-donic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol 32: 200206.
    [25] Gómezpinilla F (2008) Brainfoods: The effect of nutrients on brain function. Nat Rev Neurosci 9: 568578.
    [26] Willis LM, Shukitt-Hale BJ (2009) Recent advances in berry supplementation and age-related cognitive decline. Curr Opin Clin Nutr Metab Care 12: 91–94. doi: 10.1097/MCO.0b013e32831b9c6e
    [27] Gu Y, Nieves JW, Stern Y, et al. (2010) Food combination and Alzheimer disease risk: A protective diet. Arch Neurol 67: 699706.
    [28] Nyaradi A, Li J, Hickling S, et al. (2013) The role of nutrition in children's neurocognitive development, from pregnancy through childhood. Front Hum Neurosci 7: 97.
    [29] Prado EL, Dewey KG (2014) Nutrition and brain development in early life. Nutr Rev 72: 267284.
    [30] Keunen K, Elburg RMV, Bel FV, et al. (2014) Impact of nutrition on brain development and its neuroprotective implications following preterm birth. Pediatr Res 77: 148155.
    [31] Georgieff MK, Rao R, (2001) The role of nutrition in cognitive development. In: Nelson CA, Luciana M, Eds.,Handbook in developmental cognitive neuroscience.Cambridge, MA: MIT Press, 491–504.
    [32] Hultman CM, Sparén P, Cnattingius S (2002) Perinatal risk factors for infantile autism. Epidemiology 13: 417423.
    [33] Dionne G, Boivin M, Seguin JR. et al. (2008) Gestational diabetes hinders language development in offspring. Pediatrics 122: 10731079.
    [34] Leonard H, Klerk N, Bourke J, et al. (2006) Maternal health in pregnancy and intellectual disability in the offspring: A population-based study. Ann Epidemiol 16: 448454.
    [35] Dodds L, Fell DB, Shea S, et al. (2011) The role of prenatal, obsteric and neonatal factors in the development of autism. J Autism Dev Disord 41: 891902.
    [36] Burdge GC, Lillycrop KA (2014) Fatty acids and epigenetics. Curr Opin Clin Nutr Metab Care 17: 156–161. doi: 10.1097/MCO.0000000000000023
    [37] Delong GR (1993) Effects of nutrition on brain development in humans. Am J Clin Nutr 57: S286S290.
    [38] Morgane PJ, Mokler DJ, Galler JR (2002) Effects of prenatal protein malnutrition on the hippocampal formation. Neurosci Biobehav Rev 26: 471–483. doi: 10.1016/S0149-7634(02)00012-X
    [39] Rosales FJ, Reznick JS, Zeisel SH (2009) Understanding the role of nutrition in the brain and behavioral development of toddlers and preschool children: Identifying and addressing methodological barriers. Nutr Neurosci 12: 190–202. doi: 10.1179/147683009X423454
    [40] Mccann JC, Ames BN (2005) Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 82: 281–295.
    [41] Innis SM (2007) Dietary (n-3) fatty acids and brain development. J Nutr 137: 855–859. doi: 10.1093/jn/137.4.855
    [42] Wu A, Ying Z, Gomezpinilla F (2007) Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma 24: 1587–1595.
    [43] De Souza AS, Fernandes FS (2011) Effects of maternal malnutrition and postnatal nutritional rehabilitation on brain fatty acids, learning, and memory. Nutr Rev 69: 132–144.
    [44] Lozoff B, Georgieff MK (2006) Iron deficiency and brain development. Semin Pediatr Neurol 13: 158–165.
    [45] Zimmermann MB (2011) The role of iodine in human growth and development. Semin Cell Dev Biol 22: 645–652.
    [46] Greenwood CE, Winocur G (2005) High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging 26: 42–45.
    [47] Molteni R, Barnard RJ, Ying Z, et al. (2002) A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 112: 803–814.
    [48] Rice D, Barone S (2000) Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. Environ Health Perspect 108: 511533.
    [49] Couperus JW,Nelson CA,(2006) Early brain development and plasticity. In: McCartney K, Phillips D, Eds.,The Blackwell Handbook of Early Childhood Development.Malden, MA: Blackwell Publsihing,85105.
    [50] Benton D (2010) The influence of dietary status on the cognitive performance of children. Mol Nutr Food Res 54: 457–470.
    [51] Levitsky DA, Strupp BJ (1995) Malnutrition and the brain: Changing concepts, changing concerns. J Nutr 125: 2212S–2220S. doi: 10.1093/jn/125.suppl_8.2212S
    [52] Penido AB, Rezende GH, Abreu RV, et al. (2012) Malnutrition during central nervous system growth and development impairs permanently the subcortical auditory pathway. Nutr Neurosci 15: 31–36. doi: 10.1179/1476830511Y.0000000022
    [53] Roseboom TJ, Painter RC, Van Abeelen AF, et al. (2011) Hungry in the womb: What are the consequences? Lessons from the Dutch famine. Maturitas 70: 141–145.
    [54] Kerac M, Postels DG, Mallewa M, et al. (2014) The interaction of malnutrition and neurologic disability in Africa. Semin Pediatr Neurol 21: 42–49. doi: 10.1016/j.spen.2014.01.003
    [55] Jacka FN, Pasco JA, Mykletun A, et al. (2010) Association of western and traditional diets with depression and anxiety in women. Am J Psychiatry 167: 305–311. doi: 10.1176/appi.ajp.2009.09060881
    [56] Jacka FN, Pasco JA, Mykletun A, et al. (2011) Diet quality in bipolar disorder in a population-based sample of women. J Affective Disord 129: 332–337. doi: 10.1016/j.jad.2010.09.004
    [57] Forsyth AK, Williams PG, Deane FP (2011) Nutrition status of primary care patients with depression and anxiety. Aust J Primary Health 18: 172–176.
    [58] Scarmeas N, Stern Y, Tang MX, et al. (2006) Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59: 912–921. doi: 10.1002/ana.20854
    [59] Francesco S, Francesca C, Rosanna A, et al. (2008) Adherence to Mediterranean diet and health status: A meta-analysis. BMJ 337: a1344. doi: 10.1136/bmj.a1344
    [60] Scarmeas N, Stern Y, Mayeux R, et al. (2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66: 216–225.
    [61] Eilander A, Gera T, Sachdev HS, et al. (2010) Multiple micronutrient supplementation for improving cognitive performance in children: Systematic review of randomised controlled trials. Am J Clin Nutr 91: 115–130. doi: 10.3945/ajcn.2009.28376
    [62] Schoenthaler SJ, Amos S, Doraz W, et al. (1997) The effect of randomized vitamin-mineral supplementation on violent and non-violent antisocial behavior among incarcerated juveniles. J Nutr Environ Med 7: 343–352. doi: 10.1080/13590849762475
    [63] Schoenthaler SJ, Bier ID (1999) Vitamin-mineral intake and intelligence: A macrolevel analysis of randomised controlled trials. J Altern Complementary Med 5: 125–134. doi: 10.1089/acm.1999.5.125
    [64] Zaalberg A, Nijman H, Bulten E, et al. (2010) Effects of nutritional supplements on aggression, rule-breaking, and psychopathology among young adult prisoners. Aggressive Behav 36: 117–126. doi: 10.1002/ab.20335
    [65] Buffington SA, Di PG, Auchtung TA, et al. (2016) Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell 165: 1762–1775. doi: 10.1016/j.cell.2016.06.001
    [66] Bazinet RP, Layé S (2014) Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 15: 771–785. doi: 10.1038/nrn3820
    [67] Innis S, De-La-Presa-Owens S (2001) Dietary fatty acid composition in pregnancy alters neurite membrane fatty acids and dopamine in newborn rat brain. J Nutr 131: 118–122. doi: 10.1093/jn/131.1.118
    [68] Pardo CA, Eberhart CG (2007) The neurobiology of autism. Brain Pathol 17: 434–447. doi: 10.1111/j.1750-3639.2007.00102.x
    [69] Chalon S (2006) Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukotrienes Essent Fatty Acids 75: 259–269. doi: 10.1016/j.plefa.2006.07.005
    [70] Zimmer L, Delpal S, Guilloteau D, et al. (2000) Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett 284: 25–28. doi: 10.1016/S0304-3940(00)00950-2
    [71] Aïd S, Vancassel S, Poumès-Ballihaut C, et al. (2003) Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. J Lipid Res 44: 1545–1551. doi: 10.1194/jlr.M300079-JLR200
    [72] Takeuchi T, Iwanaga M, Harada E (2003) Possible regulatory mechanism of DHA-induced anti-stress reaction in rats. Brain Res 964: 136–143. doi: 10.1016/S0006-8993(02)04113-6
    [73] Fedorova I, Alvheim AR, Hussein N, et al. (2009) Deficit in prepulse inhibition in mice caused by dietary n-3 fatty acid deficiency. Behav Neurosci 123: 1218–1225. doi: 10.1037/a0017446
    [74] Larrieu T, Hilal LM, Fourrier C, et al. (2014) Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion. Transl Psychiatry 4: e437. doi: 10.1038/tp.2014.77
    [75] Larrieu T, Madore C, Joffre C, et al. (2012) Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signalling pathway in the brain and associated anxiety-like behavior in mice. J Physiol Biochem 68: 671–681. doi: 10.1007/s13105-012-0179-6
    [76] Jones ML, Mark PJ, Waddell BJ (2013) Maternal omega-3 fatty acid intake increases placental labyrinthine antioxidant capacity but does not protect against fetal growth restriction induced by placental ischaemia-reperfusion injury. Reproduction 146: 539–547. doi: 10.1530/REP-13-0282
    [77] Li Q, Leung YO, Zhou I, et al. (2015) Dietary supplementation with n-3 fatty acids from weaning limits brain biochemistry and behavioural changes elicited by prenatal exposure to maternal inflammation in the mouse model. Transl Psychiatry 5: e641. doi: 10.1038/tp.2015.126
    [78] Labrousse VF, Nadjar A, Joffre C, et al. (2012) Short-term long chain Omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One 7: e36861. doi: 10.1371/journal.pone.0036861
    [79] Kerr M (2008) Neurodevelopmental delays associated with iron-fortified formula for healthy infants. Med Psychiatry Mental Health.
    [80] Stein Z, Susser M, Saenger G, et al. (1975) Famine and human development: The Dutch hunger winter of 1944–1945. Q Rev Biol 7: 1944–1945.
    [81] Hoek HW, Susser E, Buck KA, et al. (1996) Schizoid personality disorder after prenatal exposure to famine. Am J Psychiatry 153: 1637–1639. doi: 10.1176/ajp.153.12.1637
    [82] Susser E, Neugebauer R, Hoek HW, et al. (1996) Schizophrenia after prenatal famine: Further evidence. Arch Gen Psychiatry 53: 25–31. doi: 10.1001/archpsyc.1996.01830010027005
    [83] Susser E, Hoek HW, Brown A (1998) Neurodevelopmental Disorders after Prenatal Famine: The Story of the Dutch Famine Study. Am J Epidemiol 147: 214–216.
    [84] Millichap JG, Yee MM (2012) The Diet Factor in Attention-Deficit/hyperactivity disorder. Paediatrics 129: 330. doi: 10.1542/peds.2011-2199
    [85] Surén P, Roth C, Bresnahan M, et al. (2013) Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. J Am Med Assoc 309: 570–577. doi: 10.1001/jama.2012.155925
    [86] Grant WB, Soles CM (2009) Epidemiologic evidence supporting the role of maternal vitamin D deficiency as a risk factor for the development of infantile autism. Dermatoendocrinology 1: 223–228. doi: 10.4161/derm.1.4.9500
    [87] Blaylock RL (2009) Possible central mechanism in autism spectrum disorders, part 3: The role of excitotoxin food additives and the synergistic effects of other environmental toxins. Altern Ther Health Med 15: 56–60.
    [88] Macfabe DF, Cain DP, Rodriguez-Capote K, et al. (2007) Neurobiological effects of intraventricular propionic acid in rats: Possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders.Behav Brain Res176: 149169.
    [89] Macfabe DF, Cain NE, Boon F, et al. (2011) Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: Relevance to autism spectrum disorder. Behav Brain Res 217: 47–54. doi: 10.1016/j.bbr.2010.10.005
    [90] El-Ansary AK, Bacha AB, Kotb M (2012) Etiology of autistic features: The persisting neurotoxic effects of propionic acid. J Neuroinflammation 9: 74.
    [91] Bourgeron T (2007) The possible interplay of synaptic and clock genes in autism spectrum disorders. Cold Spring Harb Symp Quant Biol 72: 645–654. doi: 10.1101/sqb.2007.72.020
    [92] Bourgeron T (2009) A synaptic trek to autism. Curr Opin Neurobiol 19: 231–234. doi: 10.1016/j.conb.2009.06.003
    [93] Bourgeron T (2015) From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat Rev Neurosci 16: 551–563. doi: 10.1038/nrn3992
    [94] Oberman LM, Ifertmiller F, Najib U, et al. (2016) Abnormal echanisms of plasticity and metaplasticity in autism spectrum disorders and fragile X syndrome. J Child Adolesc Psychopharmacol 26: 617–624. doi: 10.1089/cap.2015.0166
    [95] Georgieff MK, Brunette KE, Tran PV (2015) Early life nutrition and neural plasticity. Dev Psychopathol 27: 411–423. doi: 10.1017/S0954579415000061
    [96] Madore C, Nadjar A, Delpech JC, et al. (2014) Nutritional n-3 PUFAs deficiency during perinatal periods alters brain innate immune system and neuronal plasticity-associated genes. Brain Behav Immun 41: 22–31. doi: 10.1016/j.bbi.2014.03.021
    [97] Lafourcade M, Larrieu T, Mato S, et al. (2011) Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci 14: 345–350. doi: 10.1038/nn.2736
    [98] Thomazeau A, Boschbouju C, Manzoni O, et al. (2016) Nutritional n-3 PUFA deficiency abolishes endocannabinoid gating of hippocampal long-term potentiation. Cereb Cortex 27: 2571–2579.
    [99] Fatemi SH, Aldinger KA, Ashwood P, et al. (2012) Consensus paper: Pathological role of the cerebellum in autism. Cerebellum 11: 777–807. doi: 10.1007/s12311-012-0355-9
    [100] Harada M, Taki MM, Nose A, et al. (2011) Non-invasive evaluation of the gabaergic/glutamatergic system in autistic patients observed by mega-editing proton MR spectroscopy using a clinical 3 tesla instrument. J Autism Dev Disord 41: 447–454. doi: 10.1007/s10803-010-1065-0
    [101] Blatt GJ, Fatemi SH (2011) Alterations in gabaergic biomarkers in the autism brain: Research findings and clinical implications. Anat Rec 294: 1646–1652. doi: 10.1002/ar.21252
    [102] Hogart A, Leung KN, Wang NJ, et al. (2009) Chromosome 15q11-13 duplication syndrome brain reveals epigenetic alterations in gene expression not predicted from copy number. J Med Genet 46: 86–93.
    [103] Xu LM, Li JR, Huang Y, et al. (2012) Autismkb: An evidence-based knowledgebase of autism genetics. Nucleic Acids Res 40: 1016–1022. doi: 10.1093/nar/gkr1145
    [104] Jamain S, Betancur C, Quach H, et al. (2002) Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry 7: 302–310. doi: 10.1038/sj.mp.4000979
    [105] Yang Y, Pan C (2013) Role of metabotropic glutamate receptor 7 in autism spectrum disorders: A pilot study. Life Sci 92: 149–153. doi: 10.1016/j.lfs.2012.11.010
    [106] Yip J, Soghomonian JJ, Blatt GJ (2007) Decreased GAD67 mrna levels in cerebellar purkinje cells in autism: Pathophysiological implications. Acta Neuropathol 113: 559–568. doi: 10.1007/s00401-006-0176-3
    [107] Aldred S, Moore KM, Fitzgerald M, et al. (2003) Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 33: 93–97. doi: 10.1023/A:1022238706604
    [108] Shinohe A, Hashimoto K, Nakamura K, et al. (2006) Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacology Biol Psychiatry 30: 1472–1477. doi: 10.1016/j.pnpbp.2006.06.013
    [109] Sutcliffe JS, Delahanty RJ, Prasad HC, et al. (2005) Allelic heterogeneity at the serotonin transporter locus (slc6a4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet 77: 265–279.
    [110] Levitt P (2011) Serotonin and the autisms: A red flag or a red herring? Arch Gen Psychiatry 68: 1093–1094. doi: 10.1001/archgenpsychiatry.2011.98
    [111] Muller CL, Anacker AM, Veenstravanderweele J (2016) The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience 321: 24–41. doi: 10.1016/j.neuroscience.2015.11.010
    [112] Mccracken JT, Mcgough J, Shah B, et al. (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347: 314–321. doi: 10.1056/NEJMoa013171
    [113] Pavăl D (2017) A Dopamine Hypothesis of Autism Spectrum Disorder. Dev Neurosci 39: 355–360. doi: 10.1159/000478725
    [114] Nakamura K, Sekine Y, Ouchi Y, et al. (2010) Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 67: 59–68. doi: 10.1001/archgenpsychiatry.2009.137
    [115] Kałuzna-Czaplińska J, Socha E, Rynkowski J (2010) Determination of homovanillic acid and vanillylmandelic acid in urine of autistic children by gas chromatography/mass spectrometry. Med Sci Monit 16: CR445–CR450.
    [116] Anderson GH, Johnston JL (1983) Nutrient control of brain neurotransmitter synthesis and function. Can J Physiol Pharmacol 61: 271–281. doi: 10.1139/y83-042
    [117] Fernstrom JD, Fernstrom MH (2007) Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 137: 1539S–1547S. doi: 10.1093/jn/137.6.1539S
    [118] Schmidt RJ, Tancredi DJ, Krakowiak P, et al. (2014) Maternal intake of supplemental iron and risk of autism spectrum disorder. Am J Epidemiol 180: 890–900. doi: 10.1093/aje/kwu208
    [119] Eyles DW, Burne TH, Mcgrath JJ (2013) Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 34: 47–64. doi: 10.1016/j.yfrne.2012.07.001
    [120] Whitehouse AJ, Holt BJ, Serralha M, et al. (2013) Maternal vitamin D levels and the autism phenotype among offspring. J Autism Dev Disord 43: 1495. doi: 10.1007/s10803-012-1676-8
    [121] Tylavsky FA, Kocak M, Murphy LE, et al. (2015) Gestational vitamin 25(OH)D status as a risk factor for receptive language development: A 24-month, longitudinal, observational study. Nutrients 7: 9918–9930. doi: 10.3390/nu7125499
    [122] Morales E, Guxens M, Llop S, et al. (2012) Circulating 25-hydroxyvitamin D3 in pregnancy and infant neuropsychological development. Pediatrics 130: e913–e920. doi: 10.1542/peds.2011-3289
    [123] Keim SA, Bodnar LM, Klebanoff MA (2014) Maternal and cord blood 25(OH)-vitamin D concentrations in relation to child development and behaviour. Paediatr Perinat Epidemiol 28: 434–444. doi: 10.1111/ppe.12135
    [124] Magnusson C, Rai D, Goodman A, et al. (2012) Migration and autism spectrum disorder: Population-based study. Br J Psychiatry 201: 109–115. doi: 10.1192/bjp.bp.111.095125
    [125] Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281. doi: 10.1056/NEJMra070553
    [126] Vinkhuyzen AA, Eyles DW, Burne TH, et al. (2016) Gestational vitamin D deficiency and autism-related traits: The Generation R Study. Mol Psychiatry 23: 240246.
    [127] Liu X, Liu J, Xiong X, et al. (2016) Correlation between Nutrition and Symptoms: Nutritional Survey of Children with Autism Spectrum Disorder in Chongqing, China. Nutrients 8: 294. doi: 10.3390/nu8050294
    [128] Egan AM, Dreyer ML, Odar CC, et al. (2013) Obesity in young children with autism spectrum disorders: Prevalence and associated factors. Child Obes 9: 125–131. doi: 10.1089/chi.2012.0028
    [129] Adams JB, Vogelaar AT, (2005) Nutritional abnormalities in autism and effects of nutritional supplementation, In: ASA's 36th National Conference on Autism Spectrum Disorders, Nashville, TN.
    [130] Strambi M, Longini M, Hayek J, et al. (2006) Magnesium profile in autism. Biol Trace Elem Res 109: 97–104. doi: 10.1385/BTER:109:2:097
    [131] Pineless SL, Avery RA, Liu GT (2010) Vitamin B12 optic neuropathy in autism. Pediatrics 126: e967–e970. doi: 10.1542/peds.2009-2975
    [132] Gong ZL, Luo CM, Wang L, et al. (2014) Serum 25-hydroxyvitamin D levels in Chinese children with autism spectrum disorders. Neuroreport 25: 23–27.
    [133] Kocovska E, Andorsdottir G, Weihe P, et al. (2014) Vitamin d in the general population of young adults with autism in the faroe islands. J Autism Dev Disord 44: 2996–3005. doi: 10.1007/s10803-014-2155-1
    [134] Filipek PA, Juranek J, Nguyen MT, et al. (2004) Relative carnitine deficiency in autism. J Autism Dev Disord 34: 615–623. doi: 10.1007/s10803-004-5283-1
    [135] Adams JB (2013) Summary of Dietary, Nutritional, and Medical Treatments for Autism-based on over 150 published research studies. Autism Reasearch Institute Publication 40-Version. Available from: http://autism.asu.edu.
    [136] Berry RC, Novak P, Withrow N, et al. (2015) Nutrition Management of Gastrointestinal Symptoms in Children with Autism Spectrum Disorder: Guideline from an Expert Panel. J Acad Nutr Diet 115: 1919–1927. doi: 10.1016/j.jand.2015.05.016
    [137] Stewart PA, Hyman SL, Schmidt BL, et al. (2015) Dietary Supplementation in Children with Autism Spectrum Disorders: Common, Insufficient, and Excessive. J Acad Nutr Diet 115: 1237–1248. doi: 10.1016/j.jand.2015.03.026
    [138] Santosh PJ, Singh J (2016) Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents. BJ Psych Adv 22: 151–161.
    [139] Brondino N, Fusar-Poli L, Panisi C, et al. (2016) Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies. J Autism Dev Disord 46: 825–839. doi: 10.1007/s10803-015-2619-y
    [140] Kumar B, Prakash A, Sewal RK, et al. (2012) Drug therapy in autism: A present and future perspective. Pharmacol Rep 64: 1291–1304. doi: 10.1016/S1734-1140(12)70927-1
    [141] Doyle CA, Mcdougle CJ (2012) Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci 14: 263–279.
    [142] Croen LA, Grether JK, Yoshida CK, et al. (2011) Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 68: 1104–1112. doi: 10.1001/archgenpsychiatry.2011.73
    [143] Aman MG, Arnold LE, Mcdougle CJ, et al. (2005) Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15: 869–884. doi: 10.1089/cap.2005.15.869
    [144] Mcdougle CJ, Scahill L, Aman MG, et al. (2005) Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 16: 1142–1148.
    [145] Buitelaar JK, Willemsen-Swinkels SHN (2000) Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 9: S85–S97. doi: 10.1007/s007870070022
    [146] Aoki Y, Yahata N, Watanabe T, et al. (2014) Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism. Brain 137: 3073–3086. doi: 10.1093/brain/awu231
    [147] Watanabe T, Abe O, Kuwabara H, et al. (2014) Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: A randomized trial. JAMA Psychiatry 71: 166–175. doi: 10.1001/jamapsychiatry.2013.3181
    [148] Geraghty ME, Bates-Wall J, Ratliff-Schaub K, et al. (2010) Nutritional interventions and therapies in autism: A spectrum of what we know: Part 2. Ican Infant Child Adolesc Nutr 2: 120–133.
    [149] Geraghty ME, Depasquale GM, Lane AE (2010) Nutritional intake and therapies in autism: A spectrum of what we know: Part 1. Ican Infant Child Adolesc Nutr 2: 62–69. doi: 10.1177/1941406409358437
    [150] Marti LF (2014) Dietary interventions in children with autism spectrum disorders-an updated review of the research evidence. Curr Clin Pharmacol 9: 335–349. doi: 10.2174/15748847113086660074
    [151] Kawicka A, Regulska-Ilow B (2013) How nutrition status, diet and dietary supplements can affect autism. A review. Rocz Panstw Zakl Hig 64: 1–12.
    [152] Curtis LT, Patel K (2008) Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): A review. J Altern Complement Med 14: 79–85. doi: 10.1089/acm.2007.0610
    [153] Kidd PM (2002) Autism, an extreme challenge to integrative medicine. Part II: Medical Management. Altern Med Rev 7: 472–499.
    [154] Kidd PM (2002) Autism, an extreme challenge to integrative medicine. Part 1: The knowledge base. Altern Med Rev 7: 292316.
    [155] Pilla SSDD, Ravisankar P, Penugonda V, et al. (2014) Dietary interventions in Autism Spectrum Disorders. AP J Psychol Med 15: 24–31.
    [156] Joanna KCE, Rynkowski JB (2011) Vitamin supplementation reduces excretion of urinary dicarboxylic acids in autistic children. Nutr Res 31: 497–502. doi: 10.1016/j.nutres.2011.06.002
    [157] Mousainbosc M, Roche M, Polge A, et al. (2006) Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnesium Res 19: 53–62.
    [158] Adams JB, Holloway C (2004) Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 10: 1033–1039. doi: 10.1089/acm.2004.10.1033
    [159] Adams JB, Audhya T, Mcdonoughmeans S, et al. (2011) Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr 11: 111. doi: 10.1186/1471-2431-11-111
    [160] Cannell JJ (2008) Autism and vitamin D. Med Hypotheses 70: 750–759. doi: 10.1016/j.mehy.2007.08.016
    [161] Jia F, Wang B, Shan L, et al. (2015) Core symptoms of autism improved after vitamin D supplementation. Pediatrics 135: e196–e198. doi: 10.1542/peds.2014-2121
    [162] Saad K, Abdel-Rahman AA, Elserogy YM, et al. (2018) Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder. J Child Psychol Psychiatry 59: 20–29. doi: 10.1111/jcpp.12652
    [163] Jia F, Shan L, Wang B, et al. (2017) Bench to bedside review: Possible role of vitamin D in autism spectrum disorder. Psychiatry Res 260: 360–365.
    [164] Politi P, Cena H, Emanuele E (2011) Dietary Supplementation of Omega-3 Polyunsaturated Fatty Acids in Autism. Handb Behav Food Nutr 88: 1787–1796.
    [165] Malow BA, Adkins KW, Mcgrew SG, et al. (2012) Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 42: 1729–1737. doi: 10.1007/s10803-011-1418-3
    [166] Reading R (2011) Melatonin in autism spectrum disorders: A systematic review and meta-analysis. Dev Med Child Neurol 53: 783–792. doi: 10.1111/j.1469-8749.2011.03980.x
    [167] Critchfield JW, Van HS, Ash M, et al. (2011) The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract 2011: 161358.
    [168] Hsiao EY, Mcbride SW, Hsien S, et al. (2013) The microbiota modulates gut physiology and behavioral abnormalities associated with autism. Cell 155: 1451–1463. doi: 10.1016/j.cell.2013.11.024
    [169] Shaaban SY, El Gendy YG, Mehanna NS, et al. (2017) The role of probiotics in children with autism spectrum disorder: A prospective, open-label study. Nutr Neurosci 2017: 1–6.
    [170] Gvozdjáková A, Kucharská J, Ostatníková D, et al. (2014) Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longevity 2014: 798957.
    [171] Geier DA, Kern JK, Davis G, et al. (2011) A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med Sci Monit 17: P115–P123.
    [172] Hardan AY, Fung LK, Libove RA, et al. (2012) A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 71: 956–961. doi: 10.1016/j.biopsych.2012.01.014
    [173] Chez MG, Buchanan CP, Aimonovitch MC, et al. (2002) Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 17: 833–837. doi: 10.1177/08830738020170111501
    [174] Elder JH (2008) The gluten-free, casein-free diet in autism: An overview with clinical implications. Nutr Clin Pract 23: 583–588. doi: 10.1177/0884533608326061
    [175] Mulloy TA, Lang R, Reilly OM, et al. (2009) Gluten-free and casein-free diets in the treatment of autism spectrum disorders: A systematic review. Res Autism Spectrum Disord 4: 328–339.
    [176] Cade R, Privette M, Fregly M, et al. (2000) Autism and Schizophrenia: Intestinal disorders. Nutr Neurosci 3: 57–72. doi: 10.1080/1028415X.2000.11747303
    [177] Whiteley P, Haracopos D, Knivsberg AN, et al. (2010) The ScanBrit randomized, controlled, single-blind study of a gluten- and casein- free dietary intervention for children with autism spectrum disorders. Nutr Neurosci 13: 87–100. doi: 10.1179/147683010X12611460763922
    [178] Evangeliou A, Vlachonikolis I, Mihailidou H, et al. (2003) Application of a ketogenic diet in children with autistic behavior: Pilot study. J Child Neurol 18: 113–118. doi: 10.1177/08830738030180020501
    [179] Rossignol DA (2009) Novel and emerging treatments for autism spectrum disorders: A systematic review. Ann Clin Psychiatry 21: 213–236.
    [180] Elrashidy O, Elbaz F, Elgendy Y, et al. (2017) Ketogenic diet versus gluten free casein free diet in autistic children: A case-control study. Metab Brain Dis 32: 1935–1941. doi: 10.1007/s11011-017-0088-z
    [181] Strickland E (2009) Eating for Autism: The 10-step Nutrition Plan to Treat Your Child's Autism, Asperger's, or ADHD. Philadelphia, PA: Da Capo Press.
  • This article has been cited by:

    1. Sebastian Aniţa, Malay Banerjee, Samiran Ghosh, Vitaly Volpert, Vaccination in a two-group epidemic model, 2021, 08939659, 107197, 10.1016/j.aml.2021.107197
    2. Klot Patanarapeelert, Wuttinant Songprasert, Nichaphat Patanarapeelert, Modeling Dynamic Responses to COVID-19 Epidemics: A Case Study in Thailand, 2022, 7, 2414-6366, 303, 10.3390/tropicalmed7100303
    3. Makbul Muksar, Enggar Tri Astuti, 2022, 2647, 0094-243X, 030001, 10.1063/5.0111894
    4. Zeeshan Ali, Faranak Rabiei, Mohammad M. Rashidi, Touraj Khodadadi, A fractional-order mathematical model for COVID-19 outbreak with the effect of symptomatic and asymptomatic transmissions, 2022, 137, 2190-5444, 10.1140/epjp/s13360-022-02603-z
    5. Samiran Ghosh, Malay Banerjee, Vitaly Volpert, E. Augeraud, M. Banerjee, J.-S. Dhersin, A. d'Onofrio, T. Lipniacki, S. Petrovskii, Chi Tran, A. Veber-Delattre, E. Vergu, V. Volpert, Immuno-Epidemiological Model-Based Prediction of Further Covid-19 Epidemic Outbreaks Due to Immunity Waning, 2022, 17, 0973-5348, 9, 10.1051/mmnp/2022017
    6. Jueliang Zhou, Zhongqi Wang, Jing Xie, 2022, Existence for Fractional SEIR Compartmental Model Involving Hilfer Fractional Derivative, 978-1-6654-6401-7, 324, 10.1109/ICEITSA57468.2022.00062
    7. Arthur Bousquet, William H. Conrad, Said Omer Sadat, Nelli Vardanyan, Youngjoon Hong, Deep learning forecasting using time-varying parameters of the SIRD model for Covid-19, 2022, 12, 2045-2322, 10.1038/s41598-022-06992-0
    8. Daohan Huang, Fenghua Wen, Shunru Li, Addressing External Shock in Urban Agglomeration: Implications From the Transmission Pattern of COVID-19 in the Beijing-Tianjin-Hebei Area, 2022, 10, 2296-2565, 10.3389/fpubh.2022.870214
    9. Samiran Ghosh, Vitaly Volpert, Malay Banerjee, An Epidemic Model with Time Delay Determined by the Disease Duration, 2022, 10, 2227-7390, 2561, 10.3390/math10152561
    10. Vitaly Volpert, Malay Banerjee, Swarnali Sharma, Epidemic progression and vaccination in a heterogeneous population. Application to the Covid-19 epidemic, 2021, 47, 1476945X, 100940, 10.1016/j.ecocom.2021.100940
    11. Samiran Ghosh, Vitaly Volpert, Malay Banerjee, An Epidemic Model with Time-Distributed Recovery and Death Rates, 2022, 84, 0092-8240, 10.1007/s11538-022-01028-0
    12. V. Rexma Sherine, P. Chellamani, Rashad Ismail, N. Avinash, G. Britto Antony Xavier, Estimating the Spread of Generalized Compartmental Model of Monkeypox Virus Using a Fuzzy Fractional Laplace Transform Method, 2022, 14, 2073-8994, 2545, 10.3390/sym14122545
    13. Alexandra Smirnova, Mona Baroonian, Reconstruction of incidence reporting rate for SARS-CoV-2 Delta variant of COVID-19 pandemic in the US, 2024, 9, 24680427, 70, 10.1016/j.idm.2023.12.001
    14. Manoj Kumar Singh, Brajesh K. Singh, Carlo Cattani, Impact of general incidence function on three-strain SEIAR model, 2023, 20, 1551-0018, 19710, 10.3934/mbe.2023873
    15. Sunil Singh Negi, Nitin Sharma, Haci Mehmet Baskonus, Dual-strain dynamics of COVID-19 variants in India: Modeling, analysis, and implications for pandemic control, 2024, 926, 03781119, 148586, 10.1016/j.gene.2024.148586
    16. Rattiya Sungchasit, Puntani Pongsumpun, Mathematical modeling and stability of SARS-CoV-2 transmission dynamics among domestic tourists in Thailand, 2024, 1598-5865, 10.1007/s12190-024-02228-8
    17. Liliya Batyuk, Natalia Kizilova, 2024, Chapter 7, 978-3-031-56491-8, 81, 10.1007/978-3-031-56492-5_7
    18. Ali Moussaoui, Mohammed Meziane, On the date of the epidemic peak, 2024, 21, 1551-0018, 2835, 10.3934/mbe.2024126
    19. Masoud Saade, Samiran Ghosh, Malay Banerjee, Vitaly Volpert, An epidemic model with time delays determined by the infectivity and disease durations, 2023, 20, 1551-0018, 12864, 10.3934/mbe.2023574
  • Reader Comments
  • © 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(11785) PDF downloads(2151) Cited by(9)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog